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CHAPTER I 
INTRODUCTION 
The major characteristic of malignant tumor cells is 
their ability to invade foreign tissues and form metastatic 
foci at sites in the body distant from the primary tumor. At 
an early stage of invasion cells detach from the primary tumor 
and migrate into the adjacent tissue, possibly guided by 
chemotactic factors. Tumor cells which penetrate lymph or 
blood vessels can spread throughout the body. Tumor cells 
which escape destruction in the lymphatic or circulatory 
system can form new colonies by extravasating through the wall 
of the vessel and initiating cellular replication. Thus, the 
formation of metastases is the end result of a continuous 
invasive process that is associated with the breach of host 
protein barriers and the dissemination of viable tumor cells 
by the circulatory system throughout the entire body of the 
host (Thorgeirsson et al, 1985; Tryggvason, 1986). 
Cancer metastasis is the major cause of treatment 
failure, morbidity, and death for patients with solid 
malignant tumors. Whereas the treatment modalities of 
surgery, chemotherapy, and radiotherapy can cure approximately 
50% of patients who develop malignant tumors, the majority of 
patients who fail to respond to these modalities succumb to 
the direct effect of the metastases or to complications 
associated with the treatment of metastases (Liotta, 1986). 
At the time of diagnosis of primary tumors, approximately 50% 
of patients already have occult micrometastic tumor colonies 
that ultimately expand and lead to direct anatomic compromise. 
A large clinically detectable metastic focus in a particular 
organ may indeed indicate the presence of numerous subliminal 
micrometastases of more recent initiation. The scattered 
anatomic deposits of metastases, the heterogeneity of their 
cellular subpopulations, and their size and age variations 
often prevent surgical removal and limit the response to 
systemic anticancer agents (Chabner et al .• 1986; Liotta, 
1986). In addition, whereas conventional therapy, such as 
chemotherapy or radiotherapy, can in some cases retard 
metastatic growth, conventional therapy can often indirectly 
lead to patient morbidity and death by compromising the immune 
response and causing complications of infectious disease 
(Liotta, 1986). 
Metastatic migration is a complex phenomenon that 
involves a series of sequential steps which include: 
detachment of cells from the primary tumor; penetration of the 
extracellular matrix and basement membrane; invasion of the 
vasculature to enter the blood circulation (intravasation); 
arrest in the capillaries at the secondary sites (attachment); 
invasion through the capillary wall (extravasation) and 
finally, colonization and proliferation in the distant 
tissues. 
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Considerable experimental evidence generated by many 
research groups has supported the proposal that invasive tumor 
cells produce matrix-degrading proteolytic enzymes (Mullins et 
~ 1983; Thorgeirsson et al.. 1985; Jones and De Clerk, 
1982; Liotta, 1986). Since the extracellular matrices of 
different tissues vary qualitatively and quantitatively with 
respect to their levels of collagens, glycoproteins, 
proteoglycans, and other matrix constituents (Alitalo and 
Vaheri, 1982; Jones and De Clerk, 1982; Liotta, 1986), it is 
likely that multiple proteolytic enzymes are responsible for 
degradation of various extracellular matrices (Jones and De 
Clerk, 1982). 
Invasive tumors with the potential to metastasize produce 
several proteolytic enzymes that may contribute to matrix 
degradation, including collagenases (Liotta, 1986; Liotta et 
~ 1982), plasminogen activators (Dano et al .• 1985; 
Goldfarb, 1983; Henry et al .• 1983), cathepsin B (Sloane and 
Honn, 1984; Qian et al .• 1989), endoglucuronidases (Nakajima 
et. al. • 1983; Nakajima et. al. • 1984; Vlodasky et. al. • 
1983), additional neutral serine proteases (Distefano et al .• 
1983; Kramer et al .• 1985; Zucker et al .• 1985), and 
procoagulants (Badenoch-Jones and Ramshaw, 1985). Tumor cells 
can also secrete lysosomal proteases, as examples, transformed 
murine fibroblasts synthesize and secrete increased amounts of 
procathepsin B (Achkar et al.. 1990) and procathepsin L 
(Gottesman et al., 1980), Morris hepatoma 7777 cells secrete 
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early or precursor forms of cathepsin C (Mainferme et al., 
1985), and a mammary cell carcinoma MCF7 secretes procathepsin 
o in response to estrogen stimulation (Mainferme et al., 1985; 
copony et al., 1989). Among the lysosomal proteinases which 
may play a role in invasion and metastasis, cathepsin B has 
been the one most extensively investigated. 
Many studies have reported a positive correlation between 
cathepsin B activity and malignant tumors (Pool et al., 1978; 
Recklies et al., 1980; Sloane et al., 1984; Koppel et al., 
1984; Keppler et al., 1988; Krepela et al. 1989, 1990; Qian et 
~ 1989). Increased secretion of cathepsin B-like enzymes 
has been observed in ascites fluid from patients with various 
kinds of malignant tumors (Pietras and Roberts, 1981; Mort et 
~ 1981; Dufek et al., 1984) and in conditioned media from 
cultured human and murine mammary carcinoma (Recklies et al., 
1982; Petrova-Skalkova et al., 1987). The molecular basis for 
the increased levels of cathepsin B activity in the tumors 
remains unknown. Possible factors include increased 
transcription, translation, post-translational processing or 
stability of cathepsin B in tumors. Furthermore, the 
distribution of cathepsin Bis often altered in tumor cells, 
being found associated with the plasma membrane (Pietras and 
Roberts, 1981; Keren and Le Crue, 1988), and secreted into 
the extracellular medium. It is not known whether this is a 
result of a cellular defect in the biosynthetic transport 
pathway in tumors, a defect in the post-translational 
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processing of cathepsin B, or 
cells of a form of cathepsin 
from the synthesis in tumor 
B which lacks amino acid 
sequences necessary to target this enzyme to lysosomes. 
Although a selective elevation in the level of mRNA for 
cathepsin B has been demonstrated in B16 melanoma cells and 
other malignant tumors (Qian et al. • 1989) , the secreted 
cathepsin B-like activity has never been purified and its 
identity to lysosomal cathepsin B has not been proven. 
Furthermore, it is not known whether lysosomal enzyme 
secretion by tumor cells is selective or whether more than one 
kind of enzyme may be secreted by a given cell type. Finally, 
for specific lysosomal proteinases, explanations at the 
cellular and molecular levels for their secretion by tumor 
cells have not been achieved. 
The goals of this study were: First to examine the 
secretion of latent and active forms of cathepsin B, cathepsin 
L and B-glucuronidase by murine fibroblasts, virally 
transformed murine fibroblasts, and several murine melanoma 
cell variants which express elevated levels of cathepsin B 
mRNA. The purpose was to determine whether these cells show 
a general decrease in the efficiency of enzyme targeting to 
lysosomes on transformation, and if secretion of lysosomal 
enzymes is specific for cathepsin B. During the course of 
these studies we observed that the cathepsin B-like activity 
secreted by B16 melanoma cells did not resemble normal 
cathepsin Bin size and immunoreactivity. Consequently, we 
5 
undertook to purify and characterize the cathepsin B-like 
enzyme secreted by murine B16 cells in order to determine 
whether these cells secrete the authentic lysosomal 
procathepsin B. 
6 
CHAPTER II 
REVIEW OF THE RELATED LITTERATURE 
The cellular Proteases 
Proteases are composed of two groups: exopeptidases 
(peptidases) which cleave either amino- or carboxy-terminal 
amino acids or dipeptides from proteins, and endopeptidases 
(proteinases) which cleave peptide bonds in the interior of 
the protein molecule. However, this distinction is not always 
clear cut as some proteases, can have both activities. 
Proteases may be further characterized as belonging to 
one of five classes depending on the mechanism of peptide bond 
cleavage catalyzed by their active centers (Barrett, 1980a). 
These five classes are: serine proteinases, cysteine 
proteinases, aspartic proteinases, metallo-proteinases and a 
fifth category which includes enzymes with different or 
undertermined catalytic mechanisms (Barrett, 1980a). Each of 
the first four classes will be briefly discussed before 
introducing the lysosomal proteinases and more specifically 
cathepsin B. 
Serine Proteinases: 
Due to extensive homologies between serine proteinases, it has 
been hypothesized that they have all diverged from one 
primitive enzyme (Hartley, 1970). This class of proteinase 
includes trypsin, chymotrypsin, elastase, coagulation factors, 
plasmin, tryptases, cathepsin G, chymases, phasminogen 
activators, and many others. They are all active at a neutral 
pH without the need of a cofactor and all share the presence 
of the amino acid serine in their active centers. Adjacent 
histidine and aspartate residues form a catalytic "triad" 
which is essential for the activity of these enzymes (Dufton, 
1990). Serine proteinases are first synthesized as inactive 
precursors that require limited proteolysis for activation 
(Moehle et al .• 1989). Serine proteinases which participate 
in coagulation are controlled by a cascade of activating 
enzymes and a system of protein proteinase inhibitors. Serine 
proteinases of particular interest in cancer metastases are 
plasmin and the plasminogen activators urokinase PA and tissue 
PA. 
Considerable experimental evidence has indicated that the 
production of plasminogen activator by tumor cells and the 
generation of plasmin by proteolytic activation of plasminogen 
is associated with various aspects of malignant 
transformation, tumor invasion, and metastasis (Bettelheim et 
~ 1984; Fairbairn and Quigley, 1980; Saksela, 1985). 
Several studies have indicated that matrix glycoproteins are 
sensitive to plasmin-mediated proteolytic degradation (Jones 
and De Clerk, 1982). Studies with human metastatic tumor cell 
lines and normal human fibroblasts have shown that the former, 
but not the latter, digest matrix glycoproteins (Jones and De 
Clerk, 1980). It has been suggested that the production of 
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plasminogen activator by invasive tumor cells and the 
generation of plasmin are key events in the hydrolysis of all 
matrix components, since glycoprotein removal from the matrix 
is required for the maximal degradation of collagens and 
elastin. 
cysteine Proteinases: 
Members of the cysteine proteinase 
cysteine residue in their active site. 
family contain a 
Also essential to 
catalysis is the presence of a neighboring histidine residue 
which functions as a general acid-general base catalyst 
(Topham et al .• 1990). Included in this group among others 
are papain from the papaya plant (Mitchel et al .• 1970), a 
developmentally regulated proteinase in Dictiostelium 
(Williams et al .• 1985), and the mammalian lysosomal enzymes 
cathepsins B, H, and L (Barrett, 1980b). The precise function 
of the lysosomal cysteine proteinases is unclear, but they are 
generally thought to play a role in intracellular protein 
degradation. Consistent with their lysosomal location, the 
mammalian cysteine proteinases are optimally active at acidic 
pH {Barrett, 1980b). However, tumor cells have been shown to 
secrete a cysteine proteinase which retains activity at 
neutral pH and may play a role in tumor metastasis {Mullins 
and Rohlrich, 1983). The lysosomal cysteine proteinases are 
synthesized as large precursors which undergo proteolytic 
maturation after exiting the Golgi apparatus {Nishimura and 
Kato, 1987a). Limited proteolysis is associated with the 
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acquisition of proteolytic activity by these enzymes. The 
secretion of active and inactive forms have been demonstrated 
(Bajkowski et al .• 1984). Inactive forms can be activated by 
limited proteolysis with cathepsin D and pepsin (Nishimura et 
~ 1989). The active cellular form of cathepsin B is 
unstable above pH 7.0, but the form secreted by tumor cells 
shows an increased tolerance to elevated pH (Mort et al .• 
1981) . 
later. 
Cathepsins Band L will be reviewed in more detail 
Calpains are ca2+ activated cysteine proteinases (Barth 
and Elce, 1981; Dayton and Schollmeryer, 1981) which in the 
presence of ca2+ may undergo translocation to the cell 
membrane followed by autolytic activation (Murachi, T., 1989). 
Two forms of calpain have been detected which differ in the 
concentrations of ca2+ required for their maximal activities 
(Mellgren, 1980). In other respects the two forms are 
similar, both are active optimally at pH 7.5, both are 
inhibited by sulfhydryl modifying reagents and exogenous 
inhibitors of cysteine proteinases and both appear to be 
composed of two subunits. Calpains have very restricted 
proteolytic activities, and their protein substrates include 
neurofilament proteins, c-protein, demin, filamin, rimentin 
and troponins I and T (Mellgren, 1980). 
Aspartic Proteinases 
Members of this family of proteinases which all 
contain an active site aspartate include pepsin, renin, and 
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cathepsin D. Pepsin, which functions in the acidic milieu of 
the stomach, is responsible for the initial steps in protein 
digestion. Renin is thought to have been originated from the 
hypothetical cathepsin D-like archetype. However, unlike 
cathepsin D it is stable and active at neutral pH and is 
highly specific for the Leu-Leu bond that generates 
angiotensin I from angiotensinogen. 
Cathepsin Dis a major proteolytic enzyme of lysosomes 
and widely distributed in animal tissues. It is presumed that 
cathepsin D plays an important role in physiological protein 
degradation and pathological processes (Barrett, 1977; 
Schimke, 1975). However, the precise role of cathepsin Dis 
still unclear, largely because the mechanism of protein 
degradation is presumably a complex and multistep process. 
Estrogen receptor positive human breast cancer cell lines 
{MCF7, ZR75-1) produce a~ 52,000 protein, identified as a 
pro-cathepsin D {Capony et al .• 1987), in response to estrogen 
treatment in culture. Procathepsin D is also produced 
constitutively at high levels in some hormone-independent cell 
lines {MDA-MB231, BT20). In addition, cathepsin D can be 
detected in primary breast cancer cells and assayed in the 
cytosol using specific monoclonal antibodies (Rochefort et 
~ 1987). In vitro, the secreted Mr 52,000 procathepsin D 
displays an autocrine mitogenic activity on MCF7 cells (Vignon 
et al.. 1986) and interacts with the mannose 6-phosphate 
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receptor via mannose 6-phosphate residues on asparagine linked 
oligosaccharide side chains (Capony et al., 1987). At acidic 
pH in vitro, this protease can also degrade the extracellular 
matrix (Briozzo et al., 1988), suggesting that it may be 
involved in mammary carcinogenesis and metastasis (Rochefort 
et al., 1987b). 
Metallo-Proteinases: 
Metallo-proteinases are characterized by the presence of 
zn2+ in their active sites. Examples include pancreatic 
carboxypeptidase, thermolysin and collagenases. This group of 
enzymes has a slightly alkaline pH optimum and is sensitive to 
inhibition by 1, 10 orthophenanthroline, EDTA and thiols. They 
seem well suited to function extracellularly and in fact 
metallo-proteinases are secreted from cells rather than being 
active intracellularly. 
Type IV collagenase, a metallo-proteinase, degrades the 
basement membrane type IV collagen (Liotta et al. , 1979) 
whereas interstitial collagenases do not cleave this molecule 
(Babel and Alanville, 1984). Type IV collagenase has been 
found in malignant tumor tissues (Liotta et al., 1979; Salo et 
~ 1982) and cultured tumor cells (Salo et al .• 1982), and 
also in proliferating human fibroblasts (Salo et al .• 1985). 
Type IV collagense has been purified from a highly metastatic 
mouse tumor ( Salo et al. • 1982; Liotta et al. , 1981) and 
cultured human mononuclear phagocytes (Garbisa et al .• 1986). 
The enzyme is a glycoprotein with a molecular weight of either 
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72, ooo or 92,000 when studied by SOS polyacrylamide gel 
electrophoresis (Salo et al.. 1982; Liotta et al.. 1981; 
Garbisa et al.. 1986). Serine and sulfhydryl proteinase 
inhibitors such as phenylmethylsulfonyl fluoride, aprotinin 
and N-ethylmaleimide do not inhibit the enzyme whereas metal 
chelators do, indicating its identity as a metalloproteinase. 
The enzyme can be activated in vitro by pretreatment with 
trypsin, plasmin sodium dodecyl sulfate or organic mercurials 
and in this aspect it resembles interstitial collagenases. 
Type IV collagenase cleaves the native type IV collagen 
molecule at a single site in the helical domain at about one 
fourth the distance from the N-terminal end (Fessler et al .• 
1984). Accordingly, the enzyme may be able to decompose the 
collagen network of basement membranes and thus facilitates 
penetration by tumor cells. 
Cathepsin B 
Cathepsin B, a cysteine proteinase with a ~ of 
approximately 26000-27000, is located in the lysosomes of 
mammalian cells (Barrett, 1977). The enzyme can function as 
an exopeptidase, an endopeptidase, and an esterase (Bajkowski 
and Frankfater, 1983a) and is optimally active below pH 7.0 
(Bajkowski and Frankfater, 1983b; Snellman, 1971). It is very 
widely distributed (Kominami et al .• 1985; Qian et al .• 1989; 
Qian et al.. 1990) and has been isolated from rat liver, 
bovine spleen and liver (Otto, 1971), and human spleen and 
liver (Barrett, 1973). Using immunochemical methods, 
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cathepsin B has been located within macrophages (Hourie et 
~ 1985) of various tissues. Important functions have been 
inferred for cathepsin B in a number of physiological and 
pathological processes including: degradation of endocytosed 
proteins (Bystryn and Perlstein, 1982); the turnover of 
intracellular proteins (Shaw and Dean, 1980); the processing 
of secreted proteins (Quinn and Yudah, 1978) and hormonal and 
neuromodulatory polypeptides (Docherty and steiner, 1982; 
steiner et al. • 1984) , tissue resorption and remodeling 
(Bayliss and Ali, 1978); inflammation (Daves et al .• 1978); 
and mediation of hormonal response (Pietras et al .• 1975) . At 
present, the full spectrum of the biological role of cathepsin 
B is still not quite clear but its very broad tissue 
distribution suggests it has important functions. 
The mature form of cathepsin B has a molecular weight of 
26 KDa. Its pH optimum is about 6 with many substrates and it 
becomes unstable above pH 7. O (Barrett, 1977). Several 
synthetic substrates are reported to be very specific to 
cathepsin B, such as carbobenzyloxy-L-alanine-L-arginine-4-
methoxy-B-naphthylamide and carbobenzyloxy-L-arginine-L-
arginine-2-naphthylamide. Fluorogenic and chromogenic 
synthetic substrates are the most common substrates used in 
enzyme assays for determination of the cathepsin B activity 
(Barrett, 1986; Bajkowski and Frankfater, 1975). 
Numerous reports have 
activities with polypeptides 
associated cathepsin 
of Mr greater than 
B-like 
26,000. 
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1~rtyrosyl-Arg-Arg-CH2Cl, a cathepsin B substrate analog, has 
been reported to covalently label three proteins having the~ 
of 39 1 000, 31,500 and 25,000 in rat islet cells (Docherty et. 
~ 1983) and in a transplantable rat insulinoma (Docherty 
et. al., 1984). The~ 31,500 form cross-reacted with anti-
rat liver cathepsin B antibodies. Pepsin treatment of the~ 
39 1 000 form converted it to a 31,500 protein which was also 
precipitated with anti-rat liver cathepsin B antibodies, 
suggesting that the 39,000 and 31,500 polypeptides are related 
as precursor to product. These workers have also found that 
cathepsin B in rat islets is synthesized initially as a 
precursor of an approximate~ of 43,000. In the insulinoma 
the~ 39,000 form was found in insulin secretory granules and 
lysosomes, whereas the~ 25,000 species was only found in the 
lysosomal fraction. Consequently, these workers have 
suggested that the larger precursor forms of cathepsin B arise 
from incomplete proteolytic processing, possibly due to their 
not being efficiently targeted to lysosomes in the insulinoma. 
The biosynthesis and processing of cathepsin B has also 
been studied in rat liver (Nishimura and Kato, 1987a, 1987b), 
and macrophages (Kominami et al .• 1988) and in normal human 
and I-cell fibroblasts (Honewinkel et. al., 1987). In each 
case the enzyme is synthesized as a precursor which is N-
glycosylated (~ of 39,000 to 44,000) and which undergoes 
proteolytic processing to yield both an active single chain 
form(~ of 29,000 to 33,000) and a two chain form (H chain, 
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Mr 25,000 to 27,000 and L-chain, ~ 4000 to 5000). In rat 
macrophages the conversion of precursor cathepsin B to the 
single chain form is blocked by inhibitors of 
metalloendopeptidases and formation of the two chain form is 
sensitive to a cysteine proteinase inhibitor, E-64 {Hara et 
~ 1988). Agents which decrease vacuolar acidity such as 
ammonium chloride, chloroquine and monensin also block the 
proteolytic maturation of cathepsin B (Hanewinkel et al .• 
1987; Nishimura et al .• 1988). 
The mRNA for rat liver cathepsin B has been cloned as the 
cDNA. The predicted translated product corresponds to a 
polypeptide having a M, of approximately 41,000 {Segundo et 
~ 1985). A comparison of the predicted sequence to the 
amino acid sequence of the mature enzyme has indentified the 
peptide bonds which are cleaved during the proteolytic 
maturation of cathepsin B. 
Human and mouse mammary explants secrete a cathepsin B-
like enzyme in culture that is larger but enzymatically and 
immunologically related to lysosomal cathepsin B (Recklies et 
~ 1982). Ascites fluid of patients with ovarian cancer and 
primary liver cancer contain a pepsin-activatable, latent 
proteinase, immunologically related to cathepsin B {Mort et 
~ 1983; Dufek et al .• 1984) . Normal mammary gland explants 
cultured in a hormone-free medium secreted a cathepsin B-like 
enzyme with a M, of 39,000 that is indistinguishable from that 
secreted by tumor cells. In contrast, the major intracellular 
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form of cathepsin B from normal mammary glands and mammary 
tumors has an average ~ of 31,000, as compared with ~ of 
21,000 for the lysosomal form in mouse liver. It has been 
suggested that cathepsin Bis processed in an organ specific 
manner and its final intracellular size may depend on the 
tissue from which it was isolated and its final function 
(Recklies and Mort, 1985). It was also suggested that the 
larger latent secreted forms of cathepsin B, often associated 
with tumor cells, are the precursor forms of cathepsin B 
secreted as a consequence of abnormal processing (Mort and 
Recklies, 1986). 
cathepsin L 
Cathepsin Lis a lysosomal cysteine proteinase with a 
stronger endopeptidase activity than any other lysosomal 
cathepsins (Katunuma and Kominami, 1983; Matsukura et al .• 
1981). The detailed physiological role of cathepsin L within 
the cell is largely unknown. However, cathepsin L is 
considered to function in the degradation of tissue proteins 
in lysosomes and also in the breakdown of extracellular matrix 
proteins (Kirschke et al .• 1982). 
Cathepsin L is initially 
glycosylated, 39KDa proenzyme 
synthesized as 
that undergoes 
an N-
multiple 
proteolytic processing steps post-translationally, generating 
mature forms of 30 and 23 KDa (Nishimura et. al.. 1988). 
Elucidation of the determined primary structure of rat 
cathepsin L with that predicted from the nucleotide sequences 
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of isolated cDNA clones has confirmed these intracellular 
processing events (Ishido et al .• 1987). Evidence has been 
obtained that an aspartate proteinase participates in the 
proteolytic processing of cathepsin L (Nishimura et al .• 
1989) . Recently it has been shown that MEP, the major 
excreted protein of transformed fibroblasts is the precursor 
form of cathepsin L (Troen et al .• 1987). 
Biosynthetic Pathway of Lysosomal Enzymes 
The targeting of lysosomal enzymes from their site of 
synthesis in the rough endoplasmic reticulum (RER) to their 
final destination in lysosomes is a multi-step process 
requiring a series of interactions between cellular components 
and protein and carbohydrate recognition signals present on 
the lysosomal enzymes (Von Figura and Hasilik, 1986; Nolan and 
Sly, 1987; Roth, 1988). In addition, many of the early steps 
in the biosynthesis and intracellular transport of lysosomal 
enzymes are the same as for membrane proteins, and secreted 
proteins. All these proteins contain a hydrophobic signal 
sequence that allows for their synthesis on membrane-bound 
polysomes of the RER and their translocation into the lumen of 
this organelle. An 11S ribonucleoprotein called a signal 
recognition particle mediates the interaction between the 
signal peptide and the ER membrane. During translocation of 
the polypeptide into the ER, the signal peptide is cleaved and 
many of these proteins acquire one or more high mannose 
oligosaccharide side chains linked to asparagine residues by 
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N-glycosidic bonds. This glycosylation step involves the 
transfer of a large preformed oligosaccharide (three glucose, 
nine mannose, and two N-acetylglucosamine residues) from a 
lipid-linked intermediate to the nascent polypeptide (Kornfeld 
and Kornfeld, 1985). The proteins then move by vesicular 
transport from the RER to the Golgi apparatus where they 
undergo a variety of post-translational modifications and are 
segregated from one another for targeting to their final 
destinations (Griffiths and Simons, 1986). While the 
mechanisms of transport of secretory proteins to the cell 
surface are unknown, the morphological pathway appears to be 
relatively simple and involves the budding of vesicles from 
the terminal compartment of the Golgi complex, commonly 
referred to as the trans Golgi network (TGN). These vesicles 
fuse directly with the plasma membrane (Griffiths et al.. 
1985). The mechanisms by which lysosomal enzymes are 
segregated from secretory proteins and membrane proteins on 
the biosynthetic transport pathway have been under intensive 
investigation. In the case of hydrolases, which comprise the 
bulk of the lysosomal content, selective transport is mediated 
by the binding of newly synthesized enzymes to receptors for 
mannose 6-phosphate (MPR) (Sly and Fischer, 1982; Von Figura 
and Hasilik, 1986). 
When proteins enter the Golgi stack from the RER, they 
undergo a variety of posttranslational modifications which can 
facilitate their targeting to their final proper destination. 
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The simple high mannose oligosaccharides on secretory and 
membrane glycoproteins are converted by glycosidases and 
glycosyl transferases to complex-sialic acid-containing 
oligosaccharide units. Although some of the oligosaccharides 
on lysosomal enzymes undergo similar processing, most acquire 
phosphomannosyl residues through the concerted action of two 
enzymes (Kornfeld, 1986; Von Figura and Hasilik, 1986). 
First, UDP-N-acetyl-glucosamine-lysosomal-enzyme N-
acetylglucosamine-phosphotransferase (phosphotransferase) 
transfers N-acetylglucosamine !-phosphate from the nucleotide 
sugar UDP-GlcNAc to selected mannose residues on the lysosomal 
enzymes to give rise to a phosphodiester intermediate. Then, 
N-acetylglucosamine-1-phosphodiester a-N-acetylglucosaminidase 
removes the N-acetylglucosamine residue. The resultant 
phosphomonoesters serve as essential components of a 
recognition marker that leads to high-affinity binding to 
mannose 6-phosphate receptors in the Golgi (Kornfeld, 1986; 
Von Figura and Hasilik, 1986). The lysosomal enzyme-MFR 
receptor complex then exits the Golgi via a coated vesicle and 
is delivered to a prelysosomal compartment which is either 
identical or functionaly similar to the endosome. Here 
dissociation of the lysosomal enzyme from the MPR occurs by 
acidification of the compartment (Gonzalez-Noriega et al .• 
1980). The receptor then recyles back to the Golgi to pick up 
another ligand molecule, and the lysosomal enzymes which 
remain behind are packages into lysosomes. About 5-20% of 
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1ysosomal enzymes escape initial recognition by the MPR and 
are cons ti tuti vely secreted. However, a portion of these 
enzymes bind to MPRs on the cell surface. These are 
internalized by endocytosis and are then delivered to the 
1ysosomes. This second pathway is called the salvage pathway 
and it accounts for 5-10% of total lysosomal enzymes delivered 
to lysosomes in fibroblasts (Vladutiue and Rattazzi, 1979). 
The various pools of receptors in the Golgi, the endosomes and 
the cell surface appear to be in rapid equilibrium because 
exogeneously added antireceptor antibodies quickly interact 
with all of the intracellular receptor (Von Figura et al .• 
1984; Sahagian, 1984). 
Two kinds of mannose-6phosphate (Man-6P) receptors have 
been identified. They are both transmembrane glycoproteins, 
one is cation-independent (MPRc1) with a Mr of275, 000 and the 
other is a cation-dependent (MPRc0 ) with a Mr of 46,000. The 
cation-dependent receptor appears to exist as an oligomer, 
probably a dimer. The receptors have similar, but not 
identifcal specificities toward phosphorylated 
oligosaccharides, preferring oligosaccharides with two 
phosphomonosesters to those with a single phosphomonoester 
(Hoflack et al .• 1987). The major difference between the two 
receptors is that the larger one has a slightly higher 
affinity for phosphomonosesters. Both receptors bind ligands 
best at slightly acidic pH values and release the ligands at 
pH 5. 5 or below, an important property of receptors that 
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transport ligands to acidified components. Recently it has 
been shown that the cation independent MPR is identical to the 
insulin-like growth factor II (IGF-II) receptor (Roth, 1988). 
All lysosomal enzymes thus far studied are synthesized as 
preproenzymes with amino-terminal extensions (Skudlarek et 
~ 1984). The signal sequence which makes up the prepiece 
is immediately cleaved after transport into the lumen of the 
ER. The propeptide is cleaved later over the course of 
several hours to several days. This process is initiated in 
a prelysosomal compartment and is thought to be finished after 
the enzymes arrive in the lysosomes (Gieselmann et al .• 1983). 
In some instances there may be further internal cleavages of 
the protein as well as carboxy-terminal processing (Erickson 
and Blobel, 1983). 
The significance of this processing is not yet fully 
understood. However, in the cases of lysosomal proteinases 
such as cathepsins B, D, and L, the pro-sequence probably 
functions as an activation peptide to keep the protease 
inactive until it is sorted from the secretory and membrane 
proteins. However, in many cases the pro-forms of lysosomal 
enzymes appear to be active. It has been speculated that in 
these instances the propeptide pieces could play a role in the 
initial folding of the protein (Gieselmann et. al .• 1983). 
After protein folding the propeptide would then become 
dispensable much like the C peptide of insulin. In addition, 
the cleavage of the propeptide could serve to stabilize 
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1ysosomal enzymes in the acidic environment of the lysosomes. 
The propeptide might also contain sorting signals necessary 
for directing the enzyme to the lysosomes. However, it has 
been shown that the native forms of some lysosomal enzymes can 
be phosphorylated in vitro by phosphotransferase, and recently 
it has been shown that the amino acid sequences required for 
the phosphorylation of cathepsin D follow the propeptide 
(Baranski et al .• 1990). 
Alternate Targeting Pathways: 
The importance of the Man 6-P recognition pathway has 
been clearly established. However, there appear to be other 
mechanisms for targeting acid hydrolases to the lysosomes. 
studies with patients suffering from I cell disease 
[mucolipidosis II 
[Mucolipidosis III 
(ML-II)] 
(ML-III)] 
and Hurler polydystrophy 
hinted to that fact. Those 
patients suffer from lack of phosphotransferase activity 
resulting in an inability to synthesize the phosphomannosyl 
recognition marker (Kornfeld, 1986; Figura and Hasilik, 
1986). As a result, newly synthesized lysosomal enzymes are 
unable to bind to the MPRs. As expected, in some cell types 
from these patients (e.g. , fibroblasts) , lysosomal enzymes are 
secreted into the extracellular milieu rather than targeted to 
the lysosomes. On the other hand, other cell types such as 
hepatocytes, Kupffer cells, and leukocytes have normal levels 
of lysosomal enzymes even though these cells are also 
deficient in phosphotransferase activity (Owada and Neufeld, 
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l982; Waheed et al .• 1982). This strongly indicates that a 
mechanism independent from the Man 6-P pathway must exist for 
targeting enzymes to the lysosomes. Attempts to identify the 
likely receptor-mediated targeting system has proved to be 
unsuccessful so far. An additional puzzling finding is that 
that MLII fibroblasts contain normal amounts of acid 
phosphatase, a soluble lysosomal enzyme known to be 
phosphorylated in normal fibroblasts. 
Lysosomal membrane proteins are targeted by a mechanism 
which is in part different from that used by soluble lysosomal 
hydrolases. The Man 6-P recognition system does not appear to 
be a component of lysosomal membrane protein sorting systems 
in the cases thus far examined (Waheed et al .• 1988). 
Recently, it was shown that alkaline phosphatase, a type II 
integral vacuolar transmembrane protein, contains a vacuolar 
sorting signal located in the cytoplasmic and/ or transmembrane 
domain (Kbonsky and Emr, 1990). 
A class of integral membrane glycoproteins specific to 
lysosomes has been identified from rat, mouse, chicken, and 
human cells (Kornfeld and Mellman, 1989), and the human forms 
are designated lysosome-associated membrane glycoprotein 
(lamp). At least four subclasses of lamp have been identified 
based on apparent molecular weight. The best studied of these 
sublcasses are lamps 1 and 2. Lamp-1 is a highly N-
glycosylated transmembrane protein. A highly conserved 
tyrosine residue found in the deduced sequence of the 
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cytoplasmic tail of lamp-1 from chickens, rodents and humans 
was discovered to be necessary for efficient transport of 
human lamp-1 to lysosomes in cos-1 cells (Williams and Fukuda, 
1990) · In addition, the position of the tyrosine residue 
relative to the membrane spanning domain and the carboxyl 
terminus was also found to determine lysosomal expression. 
correlation Between Lysosomal Protease Expression and 
Malignancy: 
Recent evidence has suggested that the cysteine 
proteinase cathepsin B facilitates tumor cell metastasis and 
may contribute to degradation of host extracellular matrices 
(Krepela et al .• 1990). Cathepsin B has been shown to have 
broad proteolytic specificity for protein substrates, 
including myosin, actin, troponin, tropomyosin, insulin, 
proteoglycans, nonhelical regions of type IV collagen, and, in 
preliminary studies, laminin (Sloane et al .• 1986). 
Many studies have attempted to correlate metastatic 
potential with the intracellular levels of cathepsin Bin the 
belief that the activity of this enzyme within the cell 
reflected its physiological function at the cell surface or in 
the extracellular space. Positive correlations have been 
observed between intracellular levels of cathepsin Band the 
metastatic phenotype in the murine B16 melanoma variants B16-
Fl and B16-F10 (Sloane et al .• 1982), in variants of B16a 
melanoma (Sloane et al .• 1984), in three Lewis lung tumors 
(Sloane et al., 1984), in three cultured Lewis lung clones 
25 
(Takenaza, 1984), in human lung tumors (Krepela et al .• 1990), 
in cultured BDX rat sarcoma variants (Koppel et al .• 1990), in 
a rat sarcoma LW13K2 which produces spontaneous metastases 
(Krepela et al .• 1989), in human primary liver cancer (Dufek 
et al .• 1984), and in colonic cancer (Keppler et. al., 1988). 
Of particular relevance to tumor invasion and metastasis 
is the increasing body of literature on the release of 
cathepsin B from human and animal tumors (Pietras and Roberts, 
1981; Bajkowski et al .• 1984). Enzymologically, the secreted 
enzymes are very similar to lysosomal cathepsin Bin terms of 
their reactivity to synthetic substrates and to inhibitors. 
It was shown that cultured explants of malignant human breast 
tumors release eleven times more cathepsin B activity than 
normal breast tissue or nonmalignant tumors (Poole et al .• 
1978; Recklies et al .• 1980). Other reports indicated 
elevation of cathepsin B activity in the pancreatic fluid of 
patients with pancreatic cancer (Rinderknecht and Renner, 
1980), in serum of women with diverse invasive neoplastic 
diseases (Pietras et al., 1981), in malignant ascites fluid 
from patients with primary liver and ovarian cancer (Dufek et 
£b 1984; Mort et al. , 1983) , in pleural effusions from 
patients with breast cancer (Petrova-Skalkova et al .• 1987), 
and in conditioned media from human and murine tumors (Quian 
et al. • 1989; Mort et al. • 1983; Recklies et al. , 1982) . 
Cathepsin Bis also reported to be associated with the plasma 
membrane in human, rat, and murine tumors (Koppel et al., 
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l984; Pietras and Roberts, 1981; Dufek et al .• 1984; Mort et 
~ 1983; Sloane et al .• 1987). 
The secreted cathepsin B-like enzyme activities are 
different from lysosomal cathepsin Bin that they have higher 
molecular weights, different isoelectric points and, unlike 
lysosomal cathepsin B, are stable above pH 7. O. A latent high 
molecular weight form of cathepsin B (40,000) has been 
identified in ascitic fluid and in culture medium of ascites 
cells from cancer patients. The latent enzyme could be 
rendered active by prior proteinase treatment (Mort et al .• 
1981). 
The increased secretion and altered cellular distribution 
of cathepsin B in tumor cells may have its origins in 
postranslational events. However, it was also shown that 
cathepsin B levels are regulated at the level of synthesis. 
The mRNA levels for cathepsins B, L, D, H, ands in normal 
fibroblasts, mouse B16 melanoma cells, variants in rat 
carcinosarcoma , and in normal rodent tissues revealed that 
only the mRNA for cathepsin Bis elevated in the malignant 
tumors (Qian et al .• 1989; 1990). In the melanoma variants 
this elevation correlated with their metastatic phenotype as 
measured by their lung colony forming potential. In addition, 
murine melanomas contain two large cathepsin B mRNA 
transcripts which are not seen in normal mouse tissues. 
However, it has been shown that all three transcripts differ 
only in the length of their 3'untranslated regions (Qian et 
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~ 1989). 
Parenteral administration of papain in mice induced 
antipapain antibodies that cross-react with cathepsin Band 
cathepsin H (Bellelli et al .• 1990). In such animals, the 
invasion of the abdominal wall tissue (in intraperitoneally 
transplanted mice) by B16 melanoma and Lewis lung carcinoma 
tumors was clearly reduced; tumor growth rates were 
significantly lowered; fewer pulmonary metastases were found, 
and the mean survival time increased up to 180%, as compared 
to the controls. However, in contrast to the positive reports 
cited above, a lack of correlation between cathepsin Band 
metastatic potential was shown in a rat prostatic 
adenocarcinoma (Lowe and Isaacs, 1984), and in variants of a 
methylchloranthrene-induced sarcoma (McLaughlin et al .• 1983) . 
Transformed mouse fibroblasts such as Kirsten-virus-
transformed NIH-3T3 (KNIH) cells secrete large amounts of a 
39-KDa glycoprotein called MEP (major excreted protein) 
(Gottesman and Sobel, 1980). MEP was later cloned from NIH3T3 
cells and was shown to be the precursor form of cathepsin L 
(Troen et al.. 1987). MEP is synthesized by transformed 
fibroblasts in quantities 20-100 fold greater than their 
nontransformed counterparts (Gottesman and Sobel, 1980). It 
represents up to 30% of the total protein secreted by KNIH 
cells, whereas it is only 0.2-0.4% of the total protein 
secreted by nontransformed NIH-3T3 cells. The increase in the 
synthesis of procathepsin Lin transformed fibroblasts is due 
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to increased mRNA levels (Gottesman et al., 1980}, but it was 
not known whether the increased secretion of procathepsin L 
was due to a defect in a cellular component of the machinery 
which targets enzymes to lysosomes, a change in the structure 
of cathepsin L, or simply a reflection of the overexpression 
(increased synthesis} of procathepsin L. Recently, it has 
been reported that the form of cathepsin L secreted by KNIH 
cells possesses the mannose 6-phosphate lysosomal marker but 
binds poorly to mannose 6-phosphate receptors (Gal and 
Gottesman, 1986; Dong et al., 1989). 
In addition to tumors which express high levels of 
cathepsin B or cathepsin L, some tumors are reported to 
produce and secrete precursor forms of other lysosomal 
proteinases. A human breast carcinoma, MCF7, secretes an 
autoactivatable procathepsin Din cell culture in response to 
estrogen stimulation (Capony et al., 1989}. Overexpression of 
human cathepsin D by a transfected rat cell line which 
normally did not secrete cathepsin D increased its malignant 
phenotype in vitro and its metastatic potency in vivo (Garcia 
et al., 1990). Morris hepatoma 7777 cells secrete early or 
precursor forms of cathepsin c (Mainferme et al., 1985). 
It is possible that some tumor cells may secrete 
unidentified proteolytic activities that have been mistakenly 
attributed to known, characterized enzymes because of similar 
substrate and inhibitor specificities. When the conditioned 
media from cultures of 38 human, murine and hamster cells was 
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examined, they were all found to contain an enzyme activity 
which was attributed to cathepsin L (Yamaguchi et al .• 1989). 
subsequently, this activity was purified from the conditioned 
media obtained from the human tumor cells HPC-YP in culture. 
The results indicated that the enzyme produced in HPC-YP cells 
differed from cathepsin L; the M.. of the tumor enzyme was 
68,000 as compared with 34,000 for human liver cathepsin L, 
and the tumor enzyme was stable to heat treatment and to 
extremes of pH (Yamaguchi et al .• 1989). It was concluded 
that the enzyme secreted by the human tumor cells, HPC-YP, 
which appeared to have cathepsin L activity was in fact 
different from normal human liver cathepsin L. 
At present, despite the well documented correlation 
between malignant transformation and increased secretion of 
lysosomal enzymes such as cathepsin Band cathepsin L, there 
remains a number of questions concerning the pathology and 
mechanism of expression of these enzymes in tumor cells. 
Among these are: 
1) What is the cellular and molecular basis for the elevated 
secretion of cathepsin Band cathepsin L by tumors? Are tumor 
cells simply less efficient at targeting lysosomal enzymes so 
that by default many are diverted to a secretory pathway and 
escape proteolytic processing, or is secretion specific for a 
given enzyme in a given tumor type? 
2) Are tumor cells defective in components of the lysosomal 
enzyme targeting system? Do they lack mannose 6-phosphate 
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receptors? Are they unable to generate a pH gradient along 
the biosynthetic transport pathway necessary for the recycling 
of MPRs? 
J} Is the mistargeting of cathepsin B by tumor cells related 
to possible tumor cell specific differences in the glycolytic 
processing of oligosaccharide side chains in lysosomal 
enzymes? Does the secreted form of cathepsin B bear a mannose 
6-phosphate signal and is it capable of binding with high 
affinity to mannose 6-phosphate receptors? 
4} What is the structure of the secreted tumor procathepsin 
B-like enzyme? Is it the high molecular weight precursor form 
of cathepsin B, a related enzyme from a different gene locus, 
or a modified enzyme which lacks the ability to be efficiently 
targeted to the lysosomes? 
In this work I have sought to address some of these 
questions. 
First, I have examined the effects of monensin on the 
secretion of cathepsin B and other lysosomal enzymes by 
transformed cells. The assumption was that cells which are 
already inefficient in receptor-dependent targeting of enzymes 
to lysosomes cannot be further stimulated to secrete high 
levels of enzymes by agents which disrupt receptor-dependent 
transport. 
Second, I have examined the immunoreactivity of the 
cathepsin B-like activities secreted by several tumor cells in 
order to determine their relationship to normal cathepsin B. 
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Third, I have purified and partially characterized a B16 
melanoma secreted cathepsin B-like activity which does not 
react with antibodies against cathepsin Bas a first step in 
determining the nature of this enzyme. 
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Materials 
CHAPTER III 
EXPERIMENTAL PROCEDURES 
N-Benzyloxycarbonyl-L-arginyl-L-arginine-7-amido-4-
methylcoumarin (Z-Arg-Arg-AMC), Z-Phe-Arg-AMC, H-Arg-AMC, Z-
Gly-Gly-Arg-AMC, and Z-Gly-Gly-Leu-AMC were from BACHEM 
Bioscience Inc. (Philadelphia, PA) or Enzyme Systems Products 
(Livermore, CA). 4-Methylumbelliferyl-B-D-glucuronide, 
monensin, cycloheximide, E64, leupeptin, diisopropyl 
fluorophosphate, 2,2-'dithiodipyridine, 4,4-'dithiodipyridine, 
and pepsin (3900 units/mg protein) were from Sigma. 
Nitrocellulose blotting papers were obtained from Schleicher 
and Schuell. Yeast phosphomannan from Hansenula holstii NRRL 
Y-2448 was the generous gift of Dr. M. E. Slodki, Northern 
Regional Research Laboratories, USDA (Peoria, IL). 
The mannose 6-phosphate receptor specific ligand, 
pentamannosyl 6-phosphate-bovine serum albumin (PMP-BSA), was 
prepared by Qiuming Gong in our laboratory. Phosphomannan was 
hydrolyzed with dilute acid to yield pentamannosyl 6-phosphate 
(PMP) and a nonhydrolyzable polysaccharide core (Slodki et 
~ 1973; Murray and Neville, 1980). PMP was then coupled to 
bovine serum albumin by reductive alkylation (Schwartz and 
Gray, 1977). The PMP-BSA product was separated form 
unincorporated PMP by chromatography on a 2.5 x 45 cm column 
of Bio-Gel P-10 (Bio-Rad) in 20 mM Tris-HCl, 200 mM NaCl, 
0 . 02% sodium azide buffer, pH 7. O. Assay of the effluent 
fractions for protein, mannose, and phosphate (Fiske and 
sublarow, 1925) gave a phosphate: mannose molar ratio of 
1: 5. 03 for PMP and a phosphate: protein molar ratio of 18. 4: 1 
for PMP-BSA. PMP-BSA was labeled using Na 125 I (Amersham Corp.) 
and Iodo-Beads (Pierce Chemical Co.) according to the 
instructions of the manufacturer. Unreacted iodine was 
separated from the labeled protein by chromatography on an 8-
ml column of Bio-Gel P-6 in 0.05 M sodium phosphate, 0.2 M 
NaCl buffer, pH 7.5. Fractions containing labeled PMP-BSA 
were then dialyzed for 96 h against 1 liter of the same buffer 
with three buffer changes. 
Reagents for sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SOS PAGE) were obtained from Bio-Rad. Other 
reagents and buffers were purchased from commercially 
available sources and were of research grade purity. 
Cell Culture: 
Murine BALB/3T3 clone A31 cells (3T3), Moloney Murine 
Sarcoma Virus-transformed BALB/3T3 cells (MMSV), human breast 
carcinoma cells (MCF7) were obtained from the American Type 
Culture Collection. MMSV and 3T3 cells were propagated in 75 
cm2 tissue culture flasks in 10 ml of Dublecco' s modified 
Eagle's medium supplemented with 100 units/ml penicillin, 100 
mg/ml streptomycin, 3. 7 mg/ml sodium bicarbonate, 4. 5 mg/ml D-
glucose (MMSV cells only) and 10% calf serum. B16 melanoma 
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and MCF7 cells were grown in 75cm2 flasks in 10 ml of minimal 
essential medium supplemented with 100 units/ml penicillin, 
100 mg/ml streptomycin, 1. 27 mg/ml sodium bicarbonate, and 10% 
heat inactivated fetal calf serum. Cells were passed every 
three days by scraping them into 10 ml of serum-free medium, 
pelleting at 500xg, and resuspending in fresh medium 
containing 10% serum at a cell density of lxl05 cells/ml. 
Preparation of Medium for the Purification of the Melanoma 
cathepsin B-like Activity: 
To obtain medium for the purification of the cathepsin B-
like enzyme, B16 F-10 cells from five confluent T75 cm
2 were 
scrapped and added to a stir-bottle containing 1 liter of 
minimal essential medium, 10% fetal calf serum, and 1 g of 
Cytodex 2 beads (Pharmacia). The cells attached to the beads 
and grew. Just prior to confluency, the media containing 
serum was discarded and the beads rinsed with incomplete 
medium 5 times allowing for a 30 min incubation at 37° c with 
each rinse. The beads were then incubated in serum-free 
minimal essential medium for 18h after which the media was 
collected, centrifuged at 500xg and filter sterilized. The 
cells were allowed to recover by incubating them with minimal 
essential medium containing 10% fetal calf serum for 24 h. 
This cycle was repeated 4 times. 
Preparation of Media and Cell Extracts for Measurement of 
Lysosomal Enzymes: 
After achieving a confluency of about 70-80% in T75 flasks 
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the cells were washed once with phosphate-buffered saline 
(calcium-and magnesium-free) and incubated for 18 h in medium 
without serum. In some cases this medium also contained 
monensin (0.03-10 µM) and/or cycloheximide (100 µM). At the 
end of this incubation period this medium was collected, 
centrifuged at 15,000xg for 10 min and the pellet discarded. 
The adherent cells were washed with phosphate-buffered saline, 
detached with a cell scraper, and counted with a model ZBI 
Coulter counter. The cells were pelleted by centrifugation 
and extracted by sonication for 30 sec. in 50mM sodium 
acetate/1.0 mM EDTA/0.02% Triton x-100, pH 5.2, as described 
previously (Qian et al. • 1989) . Cell lysates and media 
samples could be quick-frozen and stored at -20°c for later 
analysis without significant effect on the activities of the 
enzymes measured or on the proportions of latent and active 
forms. 
Measurements of Enzyme Activities 
Latent forms of cathepsins Band L were activated by a 
30-min preincubation with pepsin in activation buffer (30 mM 
dithiothreitol and 15 mM EDTA, pH 4.2) at 37°C (Qian et al .• 
1989). The ranges of pepsin concentrations which produced 
optimal activations of cathepsins Band L during the 30-min 
incubation period were 0.41-3.3 and 0.83-5.0 mg/ml, 
respectively. To measure levels of active forms of cathepsins 
B and L, samples were preincubated for 30 min at 25°C in 
activation buffer alone (Qian et al.. 1989; Bajkowski and 
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Frankfater, 1975). Latent enzyme was defined as the 
difference in the activity of samples when preincubated with 
and without pepsin. cathepsin B was measured with Z-Arg-Arg-
AMC (final concentration 94 µM) in 0.2 M citrate/phosphate 
buffer, as described previously (Qian et al .• 1989). 
cathepsin L was estimated with Z-Phe-Arg-AMC (final 
concentration 5 mM) under identical conditions. The AMC 
products were quantified with an SLM/Aminco SPF-500C 
spectrofluoromoter at excitation and emission wavelengths of 
370 and 460 nm, respectively. While Z-Arg-Arg-AMC is not 
hydrolyzed by cathepsin Land other known lysosomal cysteine 
proteinases, both cathepsin Band cathepsin L can catalyze the 
hydrolosis of Z-Phe-Arg-AMC. However, based on the kcat and ~ 
values reported for these substrates with the two enzymes from 
humans and rats {Mason, 1986; Baricos et. al; 1988), the 
individual contributions of cathepsin Band cathepsin L to the 
hydrolysis of Z-Phe-Arg-AMC could be estimated. Thus, at the 
substrate concentrations used, the Z-Phe-Arg-AMC/Z-Arg-Arg-AMC 
activity ratio for cathepsin B was calculated to be 0.13 and 
the cathepsin L/cathepsin B activity ratio for Z-Phe-Arg-AMC 
was calculated to be 1.9 {Mason, 1986; Baricos et. al .• 1988) . 
.B-Glucuronidase was measured with 1 mM 4-methylumbel-
liferyl-.B-D-glucuronide in 0.1 M citrate buffer, pH 4.8, 
essentially as described previously (Robbins, 1979). The 4-
methylumbelliferone product was quantified by fluorescence 
measurements at excitation and emission wavelengths of 365 and 
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44 s mm, respectively. 
~11 surface Receptor Binding Assays 
cell surface mannose 6-phosphate binding activity was 
measured by a modification of the procedure of Brown and 
Farquhar ( 1984) . MMSV and 3T3 cells were grown to near 
confluence in 9 cm tissue culture dishes as described above. 
The cellular monolayer was then washed with serum-free medium 
3 times and equilibrated at 4°C for 10 min. The cells were 
then incubated at 4°C with increasing amounts of 125I-labeled 
PMP-BSA for 1 h in the absence and presence of either mannose 
6-phosphate or pentamannosyl 6-phosphate (PMP) . The monolayer 
was then washed 5 times with medium and extracted with 1 ml of 
1 N NaOH. Radioactivity was determined with a Tm Analytical 
model 1191 gamma counter and protein was determined by the 
Bio-Rad micro protein assay kit according to the instructions 
of the manufacturer. Binding data were fit to the equation 
(cpmhound=Bmax [PMP-BSA] / (kd+[PMP-BSA]) with the program 
Enzfitter (Elsevier-Biosoft, Cambridge, UK). 
Purification of the Secreted Procathepsin B-like Enzyme 
Media from B16F-10 cells were collected as described 
above. The sample ( 4 1.) was then concentrated to a volume of 
25 ml and dialyzed against 50 mM phosphate buffer pH 6. 5 
overnight. It was then applied on to a concanavalin-A-
Sepharose (Sigma) column (7 ml bed volume) previously 
equilibrated with 50 mM phosphate buffer pH 6.5. The column 
was then washed with 4 volumes of buffer to remove nonabsorbed 
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proteins. The cathepsin B-like activity that bound to the 
column was eluted first by 0.lM a-methyl-D- mannoside in 50 
mM phosphate buffer, pH 6. 5, and the eluted proteins were 
labeled pool #1. The column was then incubated with 0.lM a-
methyl-D- mannoside in 50 mM phosphate buffer, pH 6.5, for 1.5 
h and eluted with the same buffer. These fractions were 
labeled pool #2. The concentration of a-methyl-D- mannoside 
was then increased to 1 Mand the proteins eluted were labeled 
as pool #3. The column was then incubated overnight with 1 M 
a-methyl-D- mannoside and then eluted the next day with the 
same buffer (pool #4). Each pool was dialyzed against 20 mM 
Tris-HCl pH 7.9. Pool 4 (opprox. 25 ml) which had the highest 
specific activity was applied to a polywax weak anion exchange 
HPLC column (The Nest Group) using multiple injections. The 
cathepsin B-like enzyme activity was eluted with a o to 1.0 M 
gradient of increasing sodium acetate, pH 7.9 at a flow rate 
of 0.5 ml/min. 
Generation of a Polyclonal Antibody against B-Galactosidase-
cathepsin B Fusion Protein: 
Polyclonal antibodies to cathepsin B were generated by 
Qiuming Gong in this laboratory. Briefly, a cDNA clone of 
mouse cathepsin B (Segundo et al .• 1985) comprising the region 
coding for the mature form of cathepsin B was subcloned into 
a bacterial expression plasmid pWR590. ~ coli strain HBl0l 
was transformed with this vector and grown to an o.o. of 0.4. 
B-Galactosidase was induced with IPTG (isopropylthio-B-
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galactoside) and the expressed 8-galactosidase-cathepsin B 
fusion protein with a molecular weight of 98,000 was isolated 
by sos-PAGE and electroelution. 
A New Zealand white rabbit was immunized with the 
purified fusion protein in complete Freund's adjuvant. The 
fusion protein injection was repeated four times with 
incomplete Freund's adjuvant at three-week intervals. Then 
the rabbit was bled and its serum was collected and stored at 
-20°c. 
western (protein) Blotting: 
SOS-PAGE was performed on samples of cell extracts, 
culture media and fractions obtained during the purification 
of the secreted cathepsin B-like activity as described 
previously (Laemmli, 1970). The gels were then electroblotted 
onto nitrocellulose in transfer buffer {25 mM Tris, 192 mM 
glycine, 20% [vol/vol] methanol [pH 8.3]) using the Bio-Rad 
miniblotter, 
manufacturer. 
according to the instructions of the 
The nitrocellulose was washed in 10 mM Tris 
hydrochloride (pH 8.0)/150 mM NaCl/0.05% Tween 20 (TBST) and 
incubated for 1 h (room temperature) in TBST plus 5% instant 
nonfat milk. Next the nitrocellulose filter was incubated 
overnight at 4°C in TBST and milk which also contained immune 
serum at a final dilution of 1:500. The following day, the 
nitrocellulose paper was washed in TBST three times for 10 min 
each and the filter incubated in TBST + milk containing anti-
rabbit-immunoglobulin G alkaline phosphatase antibody at a 
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dilution of 1: 10,000 for 1 h at room temperature. This 
solution was removed and the nitrocellulose filter was washed 
3 times with TBST. The filter was blotted semi-dry and a 
solution containing Nitro Blue Tetrazolium (300 mg/ml), 5-
bromo-4-chloro-3-indolyl phosphate {165mg/ml) in 100 mM Tris-
HCl, 100 mM NaCl, and 5 mM MgC12 , pH 9.5, was added to the 
filter for color development. Two minutes later, the reaction 
was stopped with 20 mM Tris-HCl containing 5 mM EDTA. 
Protein Alkylation: 
The purified procathepsin B-like enzyme was reduced and 
s-carboxymethylated as described {Takio et al., 1983). 
Briefly, the protein was denatured by dissolving it in 0.4 ml 
of 6 M guanidine hydrochloride in 1. 5 M Tris-HCl, pH 8. 6, 
containing EDTA (5mg/ml). Dithiolthreiotol (DTT) (5 mg) was 
then added to reduce the protein, and the solution was 
incubated for 1 hat room temperature. Iodoacetic acid, 13.4 
mg in 0.1 ml of 0.5 N NaOH was then added and the solution 
incubated for 30 min at room temperature in the dark. The 
reaction was stopped by acidifying the solution to about pH 
5. o with 6N HCl. The sample was then dialyzed against 
distilled water and lyophilized. 
Treatment with Endoglycosidase F/N-Glycosidase F: 
The purified, alkylated enzyme was dialyzed against 50 mM 
sodium acetate pH 5.0. Endoglycosidase F/N-glycosidase F (1 
unit) was added to this solution and the mixture incubated for 
18 hat 37°C (Twining, 1984). 
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&LC Gel Filtration: 
The apparent molecular weights of the procathepsin B-like 
enzyme and its pepsin-activated form were determined by gel 
filtration on a Bio-Sil TSK 250 column (600 x 7.5 mm). The 
column was equilibrated with 50 mM phosphate buffer, pH 6.0. 
The flow rate was 0.5 ml/minute. The column was standardized 
by the injection of 200 µ.l of each of the following standards: 
Blue dextran; B-Galactosidase, ~ 116,000; bovine serum 
albumin,~ 67,1000; ovalbumin, ~ 45,000; carbonic anhydrase, 
~ 29,000; calmodulin, Mr 17,000; and aprotinin, Mr 6,500. 
The void volume of the column, V0 , was set equal to the 
elution volume of blue dextran and the total liquid volume of 
the column, VT was set equal to the position of the solvent 
front obtained after each injection of a standard. The sieve 
coefficient, K0 , for each standard was calculated from its 
elution volume with the following equation (Tan et al .• 1975). 
K0 = (Ve} standard - V0 ( 1) 
VT - Vo 
A standard curve was then prepared according to the 
relationship (Tan et al .• 1975) 
K0 = A log Mr + B. ( 2) 
Either the latent or pepsin-activated procathepsin B-
like enzyme (see previous section) (200 µ.l) was applied and 
200 µ.l fractions were collected. Enzyme assays were performed 
on both the latent and the active forms of the enzyme (see 
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previous section) to determine their elution volume. sieve 
coefficients were then calculated according to equation 1 and 
molecular weights were estimated from the standard curve (eq. 
2) • 
Eguilibrium Dissociation Constant for Leupeptin with the 
cathepsin B-like Enzyme 
At pH 6.2, the equilibrium dissociation constant, K11 for 
1eupeptin with the pepsin activated latent cathepsin B-like 
enzyme was determined from the inhibition of hydrolysis of z-
Arg-Arg-AMC under first-order conditions (~>>[SJ) and enzyme 
concentrations on the order of (~) obsd. The preactivated 
enzyme was preincubated with increasing concentrations of 
leupeptin in the assay buffer at pH 6. 2 for 45 min. The 
reaction was then initiated by adding Z-Arg-Arg-AMC at a final 
concentration of 50 uM. K1 was then determined. 
ilol = 
1-vJv0 
[EoJ (3) 
by a least squares linear regression analysis of 
ilol 
1-vJv0 
vs 1 
vJv0 
(Frankfater and Kuppy, 1981). 
In this equation vi and v0 are the inhibited and uninhibited 
rates, respectively. 
Measurements of Association and Dissociation Rate for the 
Reaction of Leupeptin with the Pepsin-activated Cathepsin B-
like Enzyme 
The inhibition of the pepsin-activated cathepsin B-like 
enzyme by leupeptin was determined against the substrate z-
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Arg-Arg-AMC as described in the preceeding section. In the 
absence of inhibitor, the formation of product was linear with 
time. In the presence of inhibitor the rate progressively 
decreased in a first-order manner until the final inhibited 
rate was achieved. First-order rate constants, k', were 
calculated by fitting the fluorescence data to the equation 
F = A(l-eh) + Bt by a least squares von linerar analysis using 
the program enzfit (elsevier, Biosoft).The rate constants k 00 
and koff were determined according to equation (4) 
k 1 = k00 [ I ] + k 0 ff ( 4 ) 
from a linear regression analysis of k' vs (I] (Schultz et 
~ 1989). Values of k 00 were corrected for the presence of 
inactive inhibitor forms, the leupeptin hydrate and the 
leupeptin cyclic carbinolamine, which together represent 98% 
of the total inhibitor concentration (Schultz et. al .• 1989). 
Active Site Titration of the Pepsin-activated Cathepsin B-like 
Enzyme 
The latent cathepsin B-like enzyme was incubated with 
increasing concentrations of the stoichiometric thiol 
proteinase inhibitor E64 while simultaneously activating with 
pepsin. After a 30 minute incubation period, enzyme activity 
was measured with Z-Arg-Arg-AMC at a final concentration of 
200 µM. The concentration of the enzyme was determined by a 
least square linear regression analysis of the hydrolase 
activity remaining vs the concentration of the inhibitor E64. 
The intercept of the extrapolated linear portion of this graph 
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with the x-axis is the estimated concentration of the enzyme. 
oetermination of the Kinetic Constants kcat and Km 
The kinetic constants kcat and ~ of the pepsin-activated 
cathepsin B-like enzyme for the hydrolysis of Z-Arg-Arg-AMC 
and Z-Phe-Arg-AMC were determined by measuring the initial 
hydrolysis rate at different concentrations of substrates [(Z-
Arg-Arg-AMC: 100, 200, 500, 1000 µM); Z-Phe-Arg-AMC: 5, 25, 
50, 100 µM)]. ~ and VIDAX values were determined by a least 
square non-linear regression analysis of the hydrolase 
activity vs the concentration of the substrate using the 
following equation. 
V = Ymax---1fil. ( 5 ) 
~ + (S] 
In this equation vis the hydrolysis rate and (S] is the final 
substrate concentration. 
To calculate kcatt VIDAX was divided by the enzyme 
concentration deduced from the active site titration (see 
previous section), according to the following equation 
vmAX = kcat X [E] (6) 
Determination of Specificities (kcatl.Kn} of the Pepsin-activated 
Cathepsin B-like Enzyme with Different Substrates 
The values of kcatl~ of the cathepsin B-like enzyme with 
different substrates (H-Arg-AMC, Z-Arg-AMC, Z-Gly-Gly-Arg-AMC, 
Z-Gly-Gly-Leu-AMC) was determined by measuring its hydrolase 
activity at final substrate concentrations of 10 and 20 µM. 
Under those conditions [SJ<<~, and according to the first 
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order kinetic equation, 
V = &at [EJ [SJ (7) 
Km 
dividing the rate, v, by the enzyme concentration [eJ and the 
substrate concentration [SJ gave an estimated value for kcat,.!... 
Km 
.T.he pH Dependency of kca.L.lSm for the Hydrolysis of Z-Arg-Arg-AMC 
by the Pepsin-activated Cathepsin B-like Enzyme 
Under conditions of [SJ<<Km (see eq. 7), the hydrolysis 
rate of Z-Arg-Arg-AMC (25 µM) by the cathepsin B-like enzyme 
was measured at different pHs using the assay buffers; 3.5, 
0.2M NaCl/0.lM Na Ac, pH 3.5-5.5; 0.2M NaCl/0.lM Na2 PHO4 , pH 
6.0-7.5; 0.2M NaCl/0.lM Tris-HCl, pH 7.0-8.0. pKa values were 
determined by a least square non-linear regression analysis of 
the hydrolase activity vs the pH of the assay buffer using the 
following equation 
( 
.Keat) 
Km obs 
= .ikca.L.lSml lim 
1 + .L1[2 + Ka2 
Ka1 [H+ J 
Inhibition studies 
(8) 
The pepsin-activated cathepsin B-like enzyme was 
incubated in the presence of lmM concentrations of diisopropyl 
fluorophosphate, 2,2 1 -dithiodipyridine and 4,4 1 -
dithiodipyridine for 45 min. The hydrolysis rate of Z-Arg-
Arg-AMC (50 µM) by the enzyme was then measured as described 
before. 
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CHAPTER IV 
RESULTS 
Effects of Viral Transformation on Lysosomal Enzyme Levels: 
Table 1 shows the levels of intracellular and secreted Z-Arg-
Arg-AMC hydrolase (cathepsin B-like), Z-Phe-Arg-AMC hydrolase 
(cathepsin L-like) and B-glucuronidase activities in 3T3 and 
MMSV cells. Latent enzyme activity is defined as the 
difference in activity observed after a 30-min preactivation 
in the absence and presence of pepsin. Virtually all the 
secreted cathepsin B and cathepsin L-like activities were 
latent in the MMSV cells. On the other hand, about 30% of the 
secreted cathepsin Band L-like activities from BALB/3T3 cells 
were active in the absence of pepsin pretreatment. From the 
reported substrate specifities and rate constants for 
cathepsin Band L (Mason, 1986; Baricos et. al .• 1988), and 
assuming these are the only enzymes present which could 
hydrolyze the two substrates, virtually all the observedZ-Arg-
Arg-AMC hydrolase activity was due to cathepsin B, while at 
least 70 and 90% of the Z-Phe-Arg-AMC activity in cell lysates 
and media samples, respectively, was due to cathepsin L. 
From the results in Table 1, it can be seen that viral 
transformation of BALB/3T3 fibroblasts caused an increase in 
Table 1.Intracellular and Secreted Fonas of Lysosoaal Enzymes in Honaal and 
Transfonaed Cells in Culture•. 
Cell-assiociated activities (paol/ain/aillion cells} 
C.thepsin B-likeb Cathepsin Lc B-glucurcnidase 
Active Latent Active Latent 
3T3 11.8 (1.0) HDd 5.0 (.6) 1.9 (.22) 45.7 (1.2) 
MMSV 31.0 (2. 7) HD 16 .1 (2.2) 27.1 (2 .8) 90.3 (10.8) 
Bl6F-1 1:28.5 (9.5) 4.2 (0.2) 62.8 (3 .1) 15.3 (1.2) 126.8 (20.3) 
B16a 345.1 (25.5) 10.7 (0.7) 129.9 (11.3) 16.1 (1.4) 197.7 (14.9) 
MCF7 15.0 (1.1) HD 3.6 (0.1) 5.3 (0.3) 415.4 (14.4) 
Secreted• activities (pmol/•in/aillion £!!.llU 
cathepsin B-like cathepsin L B-glucorcnidase 
3T3 7.9 (0.2) 62.6 (2.9) 43.2 (2.5) 
MMSV 131.1 (17.5) 1717.4 (40.1) 88.3 (2,8) 
B16F-1 92.8 (1.2) 265.9 (21.9) 35.0 (1.9) 
Bl6a 146.4 (2.0) 181.4 (6,9) 12.8 (0.9) 
MCF7 2.7 (0,1) 19.1 (1.3) 16.3 (1.6) 
•3T3, BJ\LBc/3T3 fibroblasts; MMSV, Moloney Murin• Sarcoaa Transfonaed BJ\LB 3T3 
cells; Bl6F-l and Bl6a, B16 aurine aelanoma variants having low and high 
metastatic potentials; MCF7, human breast carcinoaa. The nuabers in parenthe-
sis are the standard errors of three determinations. 
bcathepsin B-like activity determined with 94 µM Z-Arg-Arg-AMC 
ccathepsin L activity determined with 5 µM Z-Phe-Arg-AMC 
~tent cathepsin B-like is defined as the increase in Z-Arg-Arg-AMC 
activity after pepsin pretreataent. However, treat.ant of cell extracts 
with pepsin generally reduced the Z-Arg-Arg-AMC activity by 10-201. Thus 
latent cathepain B could not be eatiaated in 3T3, NMSV, and MCF7 calla. 
8 All secreted cathepain B-like and cathepain L activities are latent 
except in the BAI.Bc/3T3 cells where about 301 of the secreted ena:r-• are 
active in the absence of pepsin pretreataent. 
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cellular levels of cathepsin B, cathepsin L, and B-
glucuronidase, and a dramatic increase in the amounts of 
latent cathepsin B (17-fold} and latent cathepsin L (27-fold} 
secreted into the culture medium. A less dramatic (2-fold} 
but statistically significant increase in B-glucuronidase 
secretion was also seen. Although it has been well documented 
that fibroblasts secrete increased amounts of procathepsin L 
in response to malignant transformation (Gottesman, 1978; Gal 
and Gottesman, 1986; Denhardt et al.. 1986; Troen et al.. 
1987}, it has not been previously reported that cathepsin B 
and B-glucuronidase secretion are also elevated after viral 
transformation. While it could be estimated that cell 
extracts contained similar amounts of active cathepsin Band 
cathepsin L, the media from both transformed and 
nontransformed 3T3 cells contained much more latent cathepsin 
L than latent cathepsin B (perhaps as much as 50- and 30-fold 
more, respectively}. MMSV cells also contained measureable 
levels of latent cathepsin L but cellular latent cathepsin B 
could not be detected. 
Effects of Monensin and Cycloheximide on Lysosomal Enzyme 
Levels in BALB/3T3 and MMSV-transformed BALB/3T3 Cells 
Figure 1 shows the effects of an 18 h preincubation of 
3T3 cells with increasing concentrations of monensin on 
cellular and secreted cathepsin Band cathepsin L activities. 
It can be seen that cathepsin B secretion increased with 
increasing monensin concentrations between o. 03 µM and o .1 µM, 
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Fig. 1. Dose dependency of monensin on cellular and secreted 
ievels of cathepsin Band cathepsin Lin BALB/3T3 fibroblasts. 
The monensin concentrations varied from 0. 03 to 10 µM. Active 
and latent forms of cathepsin Band cathepsin L were measured 
with 94 µM Z-Arg-Arg-AMC and 5 µM Z-Phe-Arg-AMC, respectively, 
before and after pretreatment with pepsin as described under 
"Experimental Procedures". About 30% of cathepsin B and 
cathepsin L secreted by BALB/3T3 cells were already active. 
Pepsin sometimes caused a 10-20% decrease in cathepsin Bin 
cell lysates. In those cases the levels of latent cathepsin 
B could not be determined. Some of the error bars in this 
figure were smaller than the symbols. 
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and then plateaued between 0.3 µMand 10 µM. Figures 2 and 3 
compare the effect of monensin on the secretion of cathepsins 
Band L by 3T3 and MMSV cells. It can be seen that treatment 
of 3T3 cells with monensin causes a (4.3- and 7.3-fold 
increase) in the amounts of latent cathepsin Band cathepsin 
L, respectively, in serum-free medium. Monensin also caused 
an increase in the amount of latent enzymes recovered from 3T3 
lysates. These increases were greatly reduced (85-90%) by 100 
µM cylcloheximide, indicating that the latent enzymes secreted 
in the presence of monensin were newly synthesized. In 
contrast, the already high levels of secretion of latent 
cathepsin Band latent cathepsin L by MMSV cells could not be 
further stimulated by monensin. However, this secretion did 
remain cycloheximide-inhibitable (90% or greater). Fig. 4 
shows the results of a similar experiment with B-
glucuronidase. Again it can be seen that monensin stimulated 
B-glucuronidase release from 3T3 cells but not from MMSV 
cells. In this case, however, cycloheximide produced only a 
55% inhibition of the monensin-stimulated secretion of B-
glucuronidase by 3T3 cells and a 5% inhibition of enzyme 
secretion by MMSV cells, raising the possibility that a 
significant portion of the secreted B-glucuronidase activity 
was due to protein which had been synthesized prior to the 18 
h incubation period in serum-free medium. 
The lysosomotropic amines, ammonium chloride and 
chloroquine, at concentrations of 10 mM, exhibited similar 
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Fig. 2. Effects of monensin and cycloheximide on cellular and 
secreted levels of cathepsin Bin BALB/3T3 and Moloney murine 
sarcoma virus-tranformed BALB/3T3 fibroblasts. The monensin 
and cycloheximide concentrations were 3.0 and 100 µM, 
respectively. 
measured with 
Active and latent forms of cathepsin B were 
94 µM Z-Arg-Arg-AMC before and after 
pretreatment with pepsin as described under "Experimental 
Procedures". Virtually no active cathepsin B could be 
detected in media of MMSV cells, while about 30% of the enzyme 
secreted by BALB/3T3 cells was already active. Pepsin 
sometimes caused a 10-20% decrease in cathepsin B activity in 
cell lysates. In those cases the levels of latent cathepsin 
B could not be determined. 
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Fig· 3 • 
Effects of monensin and cycloheximide on cellular and 
secreted levels of cathepsin Lin BALB/3T3 and Moloney murine 
sarcoma virus-transformed BALB/3T3 fibroblasts. Monensin and 
cycloheximide concentrations were identical to those in Fig. 
2 . Active and latent forms of cathepsin L were measured with 
5 µM z-Phe-Arg-AMC before and after pretreatment with pepsin 
as described under "Experimental Procedures". It was possible 
to estimate that the majority of the Z-Phe-Arg-AMC activity 
measured in the cellular and media samples was due to 
cathepsin L (see "Experimental Procedures"). About 30% of the 
cathepsin L activity in the media samples from BALB/3T3 cells 
was already active while virtually no cathepsin L activity 
could be detected in media samples of MMSV cells in the 
absence of pepsin pretreatment. Because of the scale of the 
figure, some of the values cannot be estimated from the graph 
and are given in parenthesis. ND, not determinable. 
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Fig.4. Effects of monensin and cycloheximide on cellular and 
secreted levels of B-glucuronidase in BALB/3T3 and Moloney 
murine sarcoma virus-transformed BALB/3T3 fibroblasts. 
Monensin and cycloheximide concentrations were identical to 
those in Fig. 2. B-Glucuronidase was measured with 1 mM 4-
methylumbelliferyl-B-D-glucuronide as described under 
"Experimental Procedures". 
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effects on the secretion of the latent cathepsin B and 
cathepsin L activities from 3T3 cells. Ammonium chloride and 
chloroquine are believed to have this effect by raising the 
intravesicular pH and disrupting the biosynthetic transport of 
the newly synthesized lysosomal enzymes (Nishimura et al., 
1988) . 
rmmunodetection of Mature and Procathepsin B in MMSV-
transformed 3T3 Cells 
Western blots were performed on cell lysates and media 
samples in order to confirm that the cathepsin B-like activity 
secreted by MMSV cells was due to authentic cathepsin B. The 
antibody used was prepared by Qiuming Gong in our laboratory 
against a B-galactosidase-cathepsin B fusion protein expressed 
in ~ coli. Fig. 5 shows the immunodetection of mature and 
precursor forms of cathepsin Bin cell lysates and in cultured 
media from MMSV-transformed 3T3 cells in the presence and 
absence of monensin. In the lysate of the cells untreated 
with monensin ( lane 1) a 28 kDa band was detected which 
corresponds to the reported molecular mass of the mature form 
of cathepsin B (Barrett, 1977). The media in which these 
cells were cultured (lane 2) was found to contain a 40 KDa 
protein which reacts with the anticathepsin B antibody. This 
band corresponds to the expected size of procathepsin B based 
on its amino acid sequence deduced from the molecular sequence 
of the mouse cathepsin B cDNA (Segundo et al., 1985). When 
MMSV cells were treated with monensin for 18 h in serum-free 
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Fig. 5. Inununodetection of cathepsin Bin Cell Lysate and 
culture Media from Moloney Murine Sarcoma Virus-transformed 
BALB/3T3 Fibroblasts. Extracts and media samples from cells 
incubated for 18 hr in serum-free medium in the absence or 
presence of monensin were concentrated, separated by SDS PAGE 
and transferred to a nitrocellulose filter. Cathepsin B was 
visualized by the indirect antibody method using a polyclonal 
antibody directed against a cathepsin B-B-galactosidase fusion 
protein as described in "Experimental Procedures". Lanes 1 
and 2 (50 and 130 pmoles/min Z-Arg-Arg-AMC hydrolase activity, 
respectively) show cellular extracts and media samples from 
MMSV cells in the absence of monensin. Lanes 3 and 4 {10 and 
115 pmoles/min Z-Arg-Arg-AMC hydrolase activity, respectively) 
show cell extracts and media samples from cultured MMSV cells 
pretreated for 18 hr with 1.0 µM monensin. 
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medium, the mature form of cathepsin Bin 
diminished in quantity (lane 3) while 
the cell lysate 
the levels of 
procathepsin B secreted into the medium remained essentially 
unchanged ( lane 4) . These results closely paralleled the 
effects of monensin on the cellular and secreted levels of the 
cathepsin B-like activity from MMSV cells (see figure 2). 
cell Surface Mannose 6-Phosphate Receptor Binding Activity 
The finding that MMSV cells secrete increased amounts of 
three different lysosomal enzymes prompted two of my fellow 
student collaborators to examine the basis for the decreased 
efficiency of lysosomal enzyme targeting on viral 
transformation. 
Qiuming Gong found (Fig. 6) that the neoglycoconjugate 
PMP-BSA binds to 3T3 cells with a high affinity and in a 
mannose 6-phosphate and PMP-inhibitable manner. In contrast, 
MMSV-transformed 3T3 cells showed no measurable cell surface 
PMP-BSA binding activity, suggesting that MMSV cells either 
lack the mannose phosphate receptor required for lysosomal 
enzyme targeting, or that the receptor was no longer 
associated with the plasma membrane in MMSV cells. As an 
acidic vacuolar compartment is required for mannose phosphate 
receptor recycling to the cell surface and efficient lysosomal 
enzyme targeting, and monensin acts to alkalinize acidic 
compartments, Valerie Pracht undertook to measure vacuolar pH 
in MMSV cells. 
Measurement of Vacuolar pH: 
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Fig. 6. Binding of 1251-labeled PMP-BSA to BALB/3T3 ( e) and 
Maloney sarcoma virus-transformed BALB/3T3 (0) fibroblasts at 
4°c. The solid line for binding to the nontransformed 
fibroblasts was found to give a Kd = 9 .14 x 10-9 M and Bmax = 43 
x 103 cpm/mg of cellular protein. The remaing curves are: 
(A), binding to BALB/3T3 cells in the presence of 10 mM 
mannose 6-phosphate; and(~), binding to BALB/3T3 cells in the 
presence of 10 mM PMP. Binding studies were performed as 
described under "Experimental Procedures". The specific 
activity of 125!-labeled PMP-BSA was 44,460 cpm/ g of BSA. Data 
obtained by Qiuming Gong. 
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BALB/3T3 and MMSV-transformed 3T3 cells were allowed to 
internalize fluorescein isothiocyanate dextran by endocytosis 
for varying periods of time. The excitation spectrum of the 
cells was then measured between 400 mm and 500 mm. From the 
495 to 450 fluroescence ratio and the help of a standard 
curve, the pH of endosomal and lysosomal compartments in 3T3 
and MMSV cells were estimated. From the results in Table 2 it 
can be seen that these are about 0.5 pH units higher in MMSV 
cells than in their non-transformed counterparts. 
Activity of Lysosomal Enzymes in Murine B16 Melanoma Variants 
In Table 1 are collected the cellular and secreted Z-Arg-
Arg AMC, Z-Phe-Arg-AMC, and B-glucuronidase activities from 
murine B16F-1 and B16a melanoma variants. As before, latent 
enzyme activity is the difference in activity observed before 
and after pepsin pretreatment. Virtually all the secreted 
cathepsin B- and cathepsin L-like activities from the B16F-1 
and B16a cells were latent. 
From the results in Table 1, 
cellular and secreted cathepsin 
it can be seen that the 
B-like activities were 
elevated in the melanoma variant having the higher metastatic 
potential as measured by ability to form lung colonies after 
tail vein injection (Qian et al .• 1989). Cellular levels of 
cathepsin Land B-glucuronidase activities were also higher in 
the more metastatic B16a cell line than in the B16F-1. 
However, the more metastatic B16a variant secreted less 
cathepsin Land B-glucuronidase activities than the less 
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Table 2. Estimated Vacuolar pH in BALBc/3T3 Fibroblasts 
and Moloney murine Sarcoma virus-transformed BALBc/3T3 
Fibroblasts•. 
Estimated Vacuolar pH 
Incubation time 
BALBc/3T3 cells 
MMSV cells 
15 min 
6.40 
7.00 
2 hr 
6.05 
6.40 
24 hr 
5.30 
5.75 
•cells were incubated for the indicated period with 1 mg/ml 
fluorescein isothiocyanate dextran. The cells were then 
washed, collected by scraping and resuspended in PBS buffer, 
pH 7.4 . The average vacuolar pH was determined from ratio of 
cellular fluorescence measured at the excitation wavelengths 
of 495 nm and 450 nm with the help of a standard curve. 
Cellular fluorescence was first corrected for light scattering 
by the cells and for leakage of fluorescein dextran. 
Significant leakage was not observed. Data obtained by Valerie 
Pracht. 
66 
metastatic B16F-1 cells. 
Effects of Monensin and Cycloheximide on Lysosomal Enzyme 
Levels in B16F-1 and B16a Cells. 
Fig. 7 shows that an 18 h incubation of B16F-1 cells with 
the proton ionophore monensin (0.3 µM) produced a relatively 
moderate increase (2-fold) in the amount of latent cathepsin 
B-like activity in serum-free medium. Under the same 
conditions, B16a cells also show modest monensin induced (1.8 
fold) of latent cathepsin B-like activities secreted into 
serum-free medium. Monensin also caused only a modest 
increase in the apparent amount of procathepsin L (Fig. 8) 
secreted by both B16F-1 and B16a cells (about 2. 5-fold). 
These increases were largely independent of monensin 
concentrations between 0.1 µMand 1 µM. Monensin also caused 
an increase in the amount of latent cathepsin Band L detected 
in cell lysates from both B16F-1 and B16a cells. Media levels 
of latent cathepsin B- and cathepsin L-like activities 
secreted in the presence of monensin were substantially 
reduced (85-95%) by 100 µM cycloheximide. Cellular levels 
of latent cathepsin B- and cathepsin L-like activities which 
accumulated in the presence of monensin were also almost 
completely abolished by cycloheximide. These results indicate 
that the latent activities which accumulated in the cells and 
media in the presence of monensin were newly synthesized. 
Fig. 9 shows the results of the same experiment with B-
glucuronidase. In contrast to both the cathepsin B- and 
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Fig. 7. Effects of monensin and cycloheximide on 
cellular and secreted levels of cathepsin B-like activities in 
murine B16 F-1 and B16a melanoma cells. The monens in and 
cycloheximide concentrations were 0.3 and 100 µM, 
respectively. Active and latent forms of cathepsin B-like 
activities were measured with 94 µM Z-Arg-Arg-AMC before and 
after pretreatment with pepsin as described in "Experimental 
Procedures". Although virtually no cathepsin B-like activity 
could be detected in media samples in the absence of pepsin 
pretreatment, pepsin sometimes caused 10-20% decrease in 
cathepsin B-like activity in cell lysates. In those cases the 
levels of latent cathepsin B could not be determined. Because 
of the scale of the figure some of the values cannot be 
estimated from the graph and are given in parenthesis. ND, 
not determinable. 
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Fig. 8. Effects of monensin and cycloheximide on cellular and 
secreted levels of cathepsin L in murine B16 F-1 and B16a 
melanoma cells. Monensin and cycloheximide concentrations 
were identical to those in Fig. 4. Active and latent forms of 
cathepsin L were measured with 5 µM Z-Phe-Arg-AMC before and 
after pretreatment with pepsin as described under 
"Experimental Procedure". Virtually no cathepsin L activity 
could be detected in media samples in the absence of pepsin 
pretreatment. Because of the scale of the figure some of the 
values cannot be estimated from the graph and are given in 
parenthesis. 
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Fig. 9. Effects of monensin and cycloheximide on cellular and 
secreted levels of B-glucuronidase in murine B16 F-1 and B16a 
melanoma cells. Monensin and cycloheximide concentrations 
were identical to those in Fig. 4. B-glucuronidase was 
measured with 1 mM 4-methylumbelliferyl-B-D-glucuronide as 
described under "Experimental Procedures". 
72 
.300 
816F-1 
CJ Cells 
250 - Media 
200 
,,...... 
(I) 150 
q; 
0 
U) 
0 100 .... 
" C .E 
50 
" 0 
[ .300 ....... 
Q) 816a c:J Cells 
II) 
C 250 - Media "O ·c 
0 
L. 
::, 200 0 
::, 
c3 
I 150 m 
100 .) 
50 
0 
CONTROL MONENSIN MONENSIN + 
CYCLOHEXIMIDE 
73 
cathepsin L-like activities, the secretion of B-glucuronidase 
was highly stimulated in B16F-1 and B16a cells {18- and 7-fold 
respectively) by monensin. However, this secretion was not 
strongly inhibited by cycloheximide raising the possibility 
that a significant portion of the secreted enzyme was 
synthesized prior to the 18-h incubation period in the 
presence of monensin. 
Immunodetection of Mature and Procathepsin Bin B16a Melanoma 
Cells 
Fig. 10 shows an immunoblot of sample of cell lysates 
and culture media from B16a cells pretreated with and without 
the proton ionophore monensin. In the lysate of the cells 
untreated with monensin (lane 1), a 31 kDa band was detected 
which corresponds to the molecular weight reported for the 
active form in those cells (Docherty et al .• 1983). The media 
(lane 2) in which these cells were cultured also appears to 
contain a small quantity of an immunoreactive protein of 42 
kDa which may be procathepsin B {Segundo et al .• 1985). Upon 
treatment with monensin in a serum-free medium for 18 h, the 
mature form of cathepsin B in the cell lysate is greatly 
diminished (lane 3) while a higher molecular weight form (40 
kDa) secreted into the medium appears to be elevated (lane 
4) . It should be noted that lane 2 and 4 were heavily 
overloaded with similar amounts of latent Z-Arg-Arg-AMC 
hydrolase avtivity. The marked difference in the intensity of 
the immunoreactive bands stongly suggests that a 
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Fig. 10. Immunodetection of cathepsin Bin Cell Lysate and 
media samples from B16 murine melanoma cells. Extracts and 
media samples from cells incubated for 18 hr in serum-free 
medium in the absence or presence of monensin, were 
concentrated, separated by SDS PAGE and transferred to a 
nitrocellulose filter. Cathepsin B was visualized by the 
indirect antibody method using a polyclonal antibody directed 
against a cathepsin B-B-galactosidase fusion protein as 
Lanes 1 and 2 (250 described in "Experimental Procedures". 
and 220 pmoles/min Z-Arg-Arg-AMC hydro lase activity, 
respectively) show cellular extracts and media samples from 
B16a in the absence of monensin. Lanes 3 and 4 (75 and 220 
pmoles/min Z-Arg-Arg-AMC hydrolase activity) show cell 
extracts and media samples from cultured B16a cells pretreated 
for 18 hr with 0.3 µM monensin. Lane 5 is the purified latent 
cathepsin B-like enzyme. Lane 6 is the partially purified 
latent cathepsin B-like enzyme from pool #4 of the con-A-
Sepharose column. Lanes 7 and 8 show the purified latent 
secreted cathepsin B-like enzyme after pretreatment with 
either pepsin or a mixture of N-glycosidase F/endoglycosidase 
Fas described in "Experimental Procedures". Lanes 5-8 were 
all loaded with 200 pmoles/min Z-Arg-Arg-AMC hydrolase 
activity. 
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significant amount of the latent Z-Arg-Arg-AMC hydrolase 
activity secreted by B16 cells in the absence of monensin is 
not due to an immunoreactive procathepsin B. 
Effects of Estrogen Treatment on MCF7 cells 
Table 1 shows the effects of preincubating human breast 
carcinoma cells, MCF7 with 10 µ.M estrogen. All of the 
secreted cathepsin B-like and cathepsin L enzymes in both the 
absence and presence of estrogen were latent and required 
pepsin treatment for activation. Forty-eight hours of 
estrogen treatment had no effect on both the cellular and 
secreted enzyme activities of cathepsin B-like, cathepsin L, 
and B-glucuronidase enzymes, in contrast to the reported 
increase in procathepsin D secretion caused by estrogen 
treatment (Mainferme et. al .• 1985). 
Effects of Monensin and Cycloheximide on Lysosomal Enzyme 
Levels of MCF7 Cells in the Presence and Absence of Estrogen 
Figs. 11 and 12 show that an 18-h incubation of MC~ 
cells with the proton ionophore monensin (0.3 µ.M) in the 
absence and presence of estrogen produced the same moderate 
increase, 2.5- and 2.7-fold respectively, in the amount of 
latent cathepsin B-like and cathepsin L activities in serum-
free medium. Similarly, estrogen did not alter the magnitude 
of the monensin-induced increase in B-glucuronidase secretion 
(approximately 2-fold) by MCF7 cells (see Fig. 13) . 
Cycloheximide was able to negate the effect of monensin on the 
secretion of both latent cathepsin B-like and cathepsin L 
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Fig. 11. Effects of monensin and cycloheximide on cellular 
and secreted levels of cathepsin B-like activities in human 
breast carcinoma cells, MCF7 before and after treatment with 
10 nM estrogen for 48 hours. The monensin and cycloheximide 
concentrations were 0.3 and 100 µM, respectively. Active and 
latent forms of cathepsin B-like activities were measured with 
94 µM Z-Arg-Arg-AMC before and after pretreatment with pepsin 
as described under "Experimental Procedures". Although 
virtually no cathepsin B activity could be detected in media 
samples in the absence of pepsin pretreatment, pepsin 
sometimes caused a 10-20% decrease in cathepsin B-like 
activity in cell lysates. In those cases the levels of latent 
cathepsin B-like activity could not be determined. ND, not 
determinable. 
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Fig. 12. Effects of monensin and cycloheximide on cellular 
and secreted levels of cathepsin Lin human breast carcinoma 
cells MCF7 before and after treatment with 10 nM estrogen for 
48 hours. Monensin and cycloheximide concentrations were 
identical to those in Fig. 7. Active and latent forms of 
cathepsin L were measured with 5 µM Z-Phe-Arg-AMC before and 
after pretreatment with pepsin as described under 
"Experimental Procedures". Virtually no cathepsin L activity 
could be detected in media samples in the absence of pepsin 
treatment. 
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Fig. 13. Effects of monensin and cycloheximide on cellular 
and secreted levels of B-glucuronidase in human breast 
carcinoma cells, MCF7, before and after treatment with 10 uM 
estrogen for 48 hours. Monensin and cycloheximide 
concentrations were identical to those in Fig. 7. 8-
glucuronidase was measured with 1 mM 4-methylumbelliferyl-8-D-
glucuronide as described under "Experimental Procedures". 
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activities, but as in other cell lines had little effect on B-
glucuronidase secretion, raising the possibility that the B-
glucuronidase activity secreted into the media was synthesized 
before monensin treatment. 
Purification of the Latent Secreted Cathepsin B-like Enzyme 
from the Murine B16 F-10 Melanoma Cells 
The failure to detect significant levels of 
immunoreactive cathepsin Bin the culture medium from B16 
melanoma cells, despite the presence of relatively large 
amounts of a latent Z-Arg-Arg-AMC hydrolase activity, raised 
the possibility that the latent Z-Arg-Arg-AMC hydrolase 
activity secreted by B16 melanoma cells is not due to 
cathepsin B. Therefore I undertook to purify and characterize 
this enzyme. The purification of the latent Z-Arg-Arg-AMC 
hydrolase activity from serum free culture medium of B16-F10 
cells has been described in "Experimental Procedures". 
Chromatography on a concanavalin A-Sepharose column was used 
to separate the cathepsin B-like enzyme from bovine serum 
albumin which appeared as a major contaminant in the media 
samples even though the cells had been thoroughly washed and 
incubated in serum-free media. BSA did not bind to the 
concanavalin-A-Sepharose column as determined from the 
recovery of immunoreactive BSA in the initial column effluent. 
In contrast, over 80 percent of the Z-Arg-Arg-AMC hydrolase 
activity did bind to the column. The latent cathepsin B-like 
activity was bound so tightly to the column that it was 
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necessary to incubate the resin for 12 hrs with 1. 0 M a-
methyl-D- mannoside to recover most of the bound enzyme. 
Table 3 lists the four different enzyme pools obtained from 
the con A-Sepharose column and describes the manner in which 
they were obtained. The fold purification calculated for 
these fractions ranged from 3.3 to 19.7. Pool #4, which had 
the highest specific activity was applied to a Poly WAX LP 
weak anion exchange column and then eluted with a sodium 
acetate gradient as described in the methods section. The 
size of the fractions were typically either 0.5 or 1.0 ml. 
Fig. 14 shows a typical elution profile for A280 and Z-Arg-Arg-
AMC hydrolase activity. The cathepsin B-like enzyme eluted in 
two broad peaks suggesting that two or more protein species 
might be responsible for the Z-Arg-Arg-AMC hydrolase activity 
in the culture medium. Fig. 15 shows the results of SDS gel 
electrophoresis under reduced and denatured conditions of the 
protein fractions across the second peak which had the greater 
latent Z-Arg-Arg-AMC activity. Lanes 1-4 correspond to 
fractions 56, 57, 58 and 59. These show a predominant band 
with a molecular weight of about 67 kDa that correlates with 
the enzyme activity. These tubes contained close to 36% of 
the Z-Arg-Arg-AMC hydrolase activity applied to the Poly WAX 
LP column Their pooled specific activity was 0.903 
corresponding to a 74.7-fold purification (Table 3). Fig. 16 
shows the elution profile for the Z-Phe-Arg-AMC hydro lase 
activity from the same column. It seems clear that the latent 
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Fig. 14. Chromatography of Pool #4 from the Con-A-Sepharose 
column on a 4.6 x 100 mm Poly WAX weak anion exchange column 
in 20 mM Tris-HCl buffer pH 7.9. The column was eluted with 
a o to 1. 0 M linear sodium acetate gradient. Panel A, 
absorbance at 280 nm; Panel B, 1.0 ml fractions assayed for 
latent cathepsin B-like activity with 94 µM Z-Arg-Arg-AMC as 
described in "Experimental Procedures". 
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Fig. 15. SOS PAGE Electrophoresis of Enzyme Samples after 
High Performance Liquid Chromatography on a Poly WAX anion 
exchange column. Lanes 1 through 4 are fractions from peak 2 
in Fig. 14 which had the greatest latent Z-Arg-Arg-AMC 
hydrolase activity, and correspond to fractions 56, 57, 58 and 
59. After concentration, their Z-Arg-Arg-Arg-AMC hydrolase 
activities were approximately 100, 200, 400 and 100 pmoles 
/min, respectively. 
89 
kDa 
94• 
67 • 
43 • 
30• 
20.1 • 
1 2 3 4 
90 
Fig. 16. Chromatography of Pool #4 from the Con-A-Sepharose 
column on a 4.6 x 100 mm Poly WAX weak anion exchange column 
in 20 mM Tris-HCl buffer pH 7.9. The column was eluted with 
a o to 1.0 M sodium acetate gradient. Panel A, absorbance at 
280 mm; Panel B, 1.0 ml fractions assayed for cathepsin B-and 
cathepsin L-like activities with 5 µM Z-Phe-Arg-AMC as 
described in "Experimental Procedures". 
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cathepsin B-like enzyme also has Z-Phe-Arg-AMC hydrolase 
activity. Remarkably, one fraction in peak 1 contained an 
unusually large amount of latent Z-Phe-Arg-AMC hydrolase 
activity as confirmed by repeated measurements. The ratio of 
z-Phe-Arg-AMC to Z-Arg-Arg-AMC hydrolase activities of this 
fraction was very high suggesting that it had very little or 
no Z-Arg-Arg-AMC activity. Based on this observation it is 
presumed that this fraction also contains procathepsin L. 
Fig. 17 shows an SDS gel electrophoresis of this enzymatic 
activity under reducing and denaturing conditions. Lane 1 
corresponding to fraction 49 which contained the peak Z-Phe-
Arg-AMC hydro lase activity shows a single band of 
approximately 38 kDa which is the size expected for 
preprocathepsin L (Troen et al., 1987). There was 
insufficient amount of protein in the remaining fractions to 
be clearly visualize in the gel. 
Native Gel Electrophoresis 
Fig. 18 shows a native gel electrophoresis (non-
denaturing conditions) of the purified latent cathepsin B-like 
enzyme. The gel was overloaded with protein. This resulted 
in a major protein band and at least 2 minor bands after 
staining with Comassie blue. In order to determine which band 
contained the Z-Arg-Arg-AMC hydrolase activity, each band 
prior to staining was cut out of the gel, and then 
homogenized in 50 mM phosphate buffer, pH 6.5 containing .02% 
Triton X-100. Measurements of Z-Arg-Arg-AMC hydrolase 
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Fig. 17. SDS PAGE electrophoresis of enzyme amples after 
High Performance Liquid Chromatography on a Poly WAX anion 
exchange column. Fractions from peak 1 in Fig. 16 which had 
the greatest latent Z-Phe-Arg-AMC hydrolase activity were 
concentrated prior to electrophoresis. Lane 1 corresponds to 
fraction 49. Lanes 2, 3, 4 and 5 are fractions 48, 50, 51 and 
52 respectively. 
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Fig. 18. Native polycrylamide gel electrophoresis of the 
purified latent cathepsin B-like enzyme from B16 melanoma 
Cells. This gel was run under similar conditions as SOS PAGE 
but without SOS and reducing agents. 
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activity after activation with pepsin confirmed that only the 
major protein band contained latent cathepsin B-like activity 
(24% of the applied activity). 
Deglycosylation of the Purified Melanoma Latent Z-Arg-Arg-AMC 
Hydrolase Activity 
Fig. 19 shows the results of sos PAGE of different 
fractions obtained during the purification of the latent 
cathepsin B-like enzyme. Lane 7 is the purified enzyme after 
the ion exchange column and after reduction and alkylation 
with iodoacetic acid. Alkylation caused the enzyme to be 
significantly retarded on the gel with respect to the 
unalkylated standards. Treatment of the enzyme with 
endoglycosidase F/N-glycosidase F resulted in about a 6 KDa 
decrease in the apparant molecular weight of the purified 
alkylated enzyme (lane 8). 
Molecular Weight Determination by HPLC Gel Filtration 
The molecular weights of the purified latent cathepsin B-
like activity from B16 melanoma cells and its pepsin-activated 
form was estimated by HPLC native gel filtration on a TSK-250 
(600x7.5 mm) column as described in Methods section. Fig. 20 
shows the elution of a series of standards as indicated in its 
upper panel. The lower panel of Fig. 20 shows the 
superimposed elution profiles for the latent and pepsin-
pretreated Z-Arg-Arg-AMC hydrolase activity after each was 
applied separately to the column. The elution volume 
corresponding to each fraction was converted to a 
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Fig. 19. SOS PAGE electrophoresis of fractions obtained 
during different stages in the purification of the melanoma 
cathepsin B-like enzyme. Lane 1 contains the protein 
standards. Lane 2 is a sample of serum-free media from 
cultured B16 F-10 cells (30 pmoles Z-Arg-Arg-AMC hydrolase 
activity/sec). Lanes 3, 4, 5 and 6 are pools #1 through #4 
from the con-A-Sepharose column and contain either 30 pmoles 
Z-Arg-Arg-AMC hydrolase activity/min, (lanes 3 and 4), and 10 
pmoles Z-Arg-Arg-AMC activity /min, ( lanes 5 and 6) • Lane 7 is 
the reduced, alkylated latent cathepsin B-like enzyme and lane 
8 is the reduced, alkylated enzyme after treatment with a 
mixture of N glycosidase F/endoglycosidase Fas described in 
the Methods Section. 
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dimensionless parameter sigma as described in the legend to 
Fig. 20. The data in Fig. 20 was used to construct the 
standard curve shown in Fig. 21. From the elution position of 
the latent (arrow 1) and active (arrow 2) enzyme, their 
molecular weights were estimated to be 67.4 kDa and 55 kDa, 
respectively. The broadness of the pepsin-activated enzyme 
peak suggests that pepsin treatment leads to the generation of 
several active species which differ in size 
Active Site Titration with E-64 
Fig. 22 shows the active site titration of the purified 
latent cathepsin B-like enzyme. E-64, a known thiol protease 
inhibitor, was added to the latent enzyme in the indicated 
amounts prior to the addition of pepsin. The rationale for 
this procedure was that this might minimize the consequences 
of any subsequent inactivation or autolysis of the pepsin-
activated enzyme and would yield better estimates of enzyme 
concentration. Fig. 22 shows that up to 90% of the pepsin 
activatable Z-Arg-Arg-AMC hydrolase activity is inhibited by 
E-64. Extrapolation of the linear portion of the curve , 
indicates that 8 picomoles of E-64 is required to completely 
inhibit the enzyme activity corresponding to 0. 558 µ,g of 
protein as determined with the Bio-Rad dye binding assay 
(Methods section) . The ratio of protein to active site 
titrant yields a molecular weight estimate for the purified 
latent cathepsin B-like enzyme of 70,000, in close agreement 
with 67,000 as estimated by SDS PAGE. 
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Fig. 20. Determination of the molecular weight of the latent 
and pepsin-activated secreted cathepsin B-like enzyme from B16 
melanoma. The upper panel is the elution profile obtained for 
a series of proteins of known molecular weight after high 
performance liquid chromatography on a Bio-Sil TSK-250 gel 
filtration column. The abbreviations used are : B-Gal, B-
galactosidase; BSA, bovine serum albumin; Oval, ovalbumin; CA, 
carbonic anyhydrase; CAL ,calmodulin; Apn, Aprotinin. The 
lower panel shows the activity profile of pepsin pretreated 
and latent enzymes applied to the gel filtration column. 
Latent enzyme was measured after pepsin pretreatment (solid 
line) and active enzyme (pepsin pretreated before injection, 
dotted line) was measured with pepsin omitted from the 
activation buffer as described in "Experimental Procedures". 
Sigma, corresponding to the x-axis coordinate was calculated 
from the relationship 
Sigma = Y.F~ 
VT - Vo 
where Vp is the elution volume for a given fraction, V0 is the 
void volumne of the column determined with blue dextran, and 
VT is the total accessible volume of the column determined 
from the elution volume of the solvent front. Sigma is a 
dimensionless parameter which is independent of the size of 
the gel filtration column. 
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Fig. 21. Standard curve of molecular weight vs sieve 
coefficient for protein standards after high performance 
liquid chromatography on a Bio-Sil TSK-250 column. The 
experimental points correspond to the peak elution position of 
the standards from Fig. 20 and their molecular weight. 
Arrows 1 and 2 are respectively the peak elution positions of 
the latent and pepsin-activated Z-Arg-Arg-AMC hydrolase 
activities secreted by B16 melanoma cells. 
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Fig. 22. Active site titration of the purified latent 
cathepsin B-like enzyme from B16 melanoma cells. The active 
site titrant, E-64 at the indicated concentrations, was 
incubated with the purified latent enzyme during a 90 min 
activation period with 0.1 mg/ml of pepsin as described in 
"Experimental Procedures". The residual enzyme activity was 
measured with Z-Arg-Arg-AMC (200 µM) as the substrate. 
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Kinetic Constants of the Latent Cathepsin B-like Enzyme 
The kinetic constants kcat and ~ were determined for the 
pepsin-activated latent cathepsin B-like enzyme from melanoma 
cells against the substrates Z-Arg-Arg-AMC and Z-Phe-Arg-AMC. 
Figs. 23 and 24 show plots of velocity vs substrate 
concentration for the two substrates. Each point is an 
average of 3 measurements. ~ and VIDAX were determined by non-
linear regression fit of the rate data to the equation 
v = Ymax----Lfil using the program Enzfit (Elsevier-Biosoft, 
~ + (SJ 
Cambridge, UK) . The solid lines were calculated from the best 
fit parameters. Dividing V=x by the number of moles of the 
enzyme determined from active site titration with E-64 yielded 
kcat• In Table 4 is collected the kinetic constants for the 
hydrolysis of Z-Arg-Arg-AMC and Z-Phe-Arg-AMC by the purified 
cathepsin B-like enzyme from melanoma cells. For Z-Arg-Arg-
AMC, ~ and kcat are respectively 1.00 ± 0.29 mM and 0.188 ± 
0.040 s-1 respectively. For Z-Phe-Arg-AMC the corresponding 
constants are 121 + 0.081 µM and 0.286 + 0.012 
respectively. In contrast the authentic cathepsin B secreted 
by MMSV cells had a~ of 422 ± 21 µM for Z-Arg-Arg-AMC (Fig. 
25). The values for the~ of the cathepsin B-like enzyme 
from B16 melanoma cells and authentic cathepsin B from MMSV 
cells were significantly different (P<.025). 
Values of kcatl~ for Z-Arg-Arg-AMC and Z-Phe-Arg-AMC were 
also determined under conditions of (SJ<<Km. Under these 
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Fig. 23. Plot of velocity vs Z-Arg-Arg-AMC concentration 
for the secreted pepsin-activated cathepsin B-like enzyme from 
B16 melanoma. ~ and VDlAX values were determined by fitting 
the data points to the following equation 
V = Ymax X (SJ 
~ + [SJ 
by non-linear regression analysis (Enzfit/Elsevier-Biosoft, 
Cambridge, UK). Each point is an average of 3 measurements. 
The solid line represents the best fit curve. The parameter 
kcat was calculated as being equal to Vmax/E, where E is the 
enzyme concentration deduced after active site titration.~ 
and kcat were calculated to be 1. 00 + 0. 29 mM and .188 ± 0. 040 
s~, respectively. 
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Fig. 24. Plot of velocity vs substrate concentration (Z-Phe-
Arg-AMC) for the secreted pepsin-activated cathepsin B-like 
enzyme from B16 melanoma. ~ and Vmax values were determined 
by fitting the data points to the following equation 
V = Ym..x X [SJ 
~ + (SJ 
by non-linear regression analysis (Enzfit/Elsevier-Biosoft, 
Cambridge, UK). Each point is an average of 3 measurements. 
The solid line represents the best fit curve. kcat was 
calculated as being equal to Vmax/E, where E is the enzyme 
concentration deduced after active site titration. ~ and kcat 
were calculated to be 121 ± 0.081 µMand 0.286 ± .012 
respectively. 
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Fig. 25. Plot of velocity vs substrate concentration (Z-Arg-
Arg-AMC) for the secreted pepsin-activated cathepsin B enzyme 
from MMSV cells. Km was determined by fitting the data points 
to the following equation v = Y.m.x x [SJ 
~ X [SJ 
by non-linear regression analysis (Enzfit/Elsevier-Biosoft, 
Cambridge, UK). Each point is an average of 3 measurements. 
The solid line represents the best fit curve. 
calculated to be 0.422 + .021 mM. 
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conditions reaction rates were directly proportional to 
substrate concentration and the parameter 
calculated as being equal to v/(E][SJ. These various kinetic 
constants are collected in Table 4. 
Dependency of kca~ 
The rate of hydrolysis of Z-Arg-Arg-AMC was measured at 
a substrate concentration of 25 µM which corresponds to the 
condition (SJ<<Km ([S]=0.025xKm). Under these conditions, 
kcatf¾i=v/ [E] [SJ. Fig. 26 shows the effect of pH on kcatl¾t• 
Each experimental point is the mean and standard error of 
three determinations. The results, resemble a bell- shaped 
curve typical for cysteine proteinases such as cathepsin B 
(Bajkowski and Frankfater, 1975). The marked decline in kcatfKm 
between 7.5 and 8 may be due to an instability of the enzyme 
above pH 7.5. The data points from pH 3.5 to 7.5 were fit to 
the following equation for bell-shaped pH dependency curve 
_ _.(..=-k=cc,a~ 
1 + -1:L + 1Sai 
Kal H 
by non-linear regression analysis (Enzfit/Elsevier-Biosoft, 
Cambridge, UK). The solid line in Fig. 25 is the best fit 
curve calculated for pK81=5. 05 and pKa2=8. 04. 
Equilibrium Dissociation Constant for Leupeptin with the 
Secreted Cathepsin B-like Enzyme from B16 Melanoma 
K1 was calculated as described by Perlstein and Kezdy 
(1973) for a tightly binding competitive inhibitor according 
to the following equation 
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Table 4. Kinetic Constants of the Secreted Latent Cathepsin 
B-like Enzyme from cultured Cells after Incubation with 
Pepsin•. 
Z-Arg-Arg-AMC 
kcat ( s-r) ~ (M-1) b kcatf~ (M-ls-1) 
B16F-10 0.188±0.04 (1. 00±0. 290) X 10-3 188 
MMSV ND (0.422±0.02) X 10-3 ND 
Z-Phe-Arg-AMC 
B16F-10 0.286±0.012 (0.121±0.081) X 10~ 2351 
•B16F-10, B16 murine melanoma variant; MMSV, Moloney Murine 
Sarcoma Transformed BALB 3T3 cells. Values were determined by 
non-linear regression analysis (Enzfit / Elsevier-Biosoft, 
Cambridge, UK) and are presented with the estimates of the 
standard errors. 
bThe values for~ are significantly different ( P<0.025 ). 
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Fig. 26. Dependency of kcatl~ on pH of the Activated Purified 
Latent cathepsin B-like Enzyme at 25°C. Rates were measured 
with [ Z-Arg-Arg-AMCJ = 25 µ.M. This concentration is about 50-
fold less than~ such that the rate of substrate hydrolysis 
is directly proportional to kcatl~. The points are the means 
and standard error of the means of 3 determinations. The 
solid line was calculated from the equation 
161 = 
~ obs 
for the data points from 3. 5 to 7. 5. 
(kcatf~) lim' pK.1 , and pKa2 were 6. 4, 
respectively. 
Best estimates of 
5.05, and 8.04, 
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In this equation k0 and ki are either first-order rate 
constants or initial rates for substrate hydrolysis ((SJ<<Km) 
in the absence and presence of inhibitor, and (AT) and (ET) are 
total aldehyde and total enzyme concentration, respectively. 
Fig. 27 shows a plot of these data at pH 6.2. From the slope, 
~ was calculated to be (1.70 ± .212) xlO~ M. As only 2% of 
leupeptin is present as the active (aldehyde) inhibitor form, 
in equilibrium with unreactive species (Schultz et al., 1989) 
the true K1 is 3. 4x10-
11 M. 
Rate Constants for the Association-Dissociation of the 
Melanoma Secreted Cathepsin B-like Enzyme with Leupeptin 
The rate of association of leupeptin to the pepsin-
activated cathepsin B-like enzyme was determined by measuring 
time dependent changes in the hydrolysis of Z-Arg-Arg-AMC in 
the presence of leupeptin. In the absence of leupeptin, the 
fluorescence due to the formation of the AMC product was 
linear with time. In the presence of leupeptin the 
fluorescence due to product formation obeyed the relationship 
F = A(l - e~) + Bt 
In this equation, A is the fluorescence change during the 
presteady state phase of inhibitor binding, Bis the rate of 
fluorescence change during the steady state, and k is the 
pseudofirst order rate constant for attainment of the 
inhibited state. Fluorescence data was fit to this equation 
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Fig. 27. Inhibitions of cathepsin B-like enzyme-catalyzed 
hydrolysis of Z-Arg-Arg-AMC by leupeptin at 25°C in o. 2 M 
citrate/phosphate buffer pH 6.2. So= 50 µM, and I 0 varied 
from 0.2 x 10~ M to 6.66 x 10 ~ M. Each point is the average 
of 3 determinations. The solid line was calculated by a least 
squares linear regression analysis to give a K1 = 1.70 ± 0.21 
X 10-9 M. 
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by a least squares linear regression analysis using the 
program Enzfit (Elsevier-Biosoft, Cambridge, UK). Values for 
k are collected in Table 5. The pseudofirst order rate 
constant, k, has the following meaning k = k 00 [IA] + k 0 ff where 
k
00 
is a second order rate constant for association of 
leupeptin with enzyme and k 0 ff is a first order dissociation 
rate constant for decomposition of the enzyme leupeptin 
complex (Bartlet and Marlow, 1987). Fig. 28 shows a plot of 
k vs [IA], the concentration of the active inhibitor form. 
From the slope and intercept k 00 was found to be 4.53 + 0.55 x 
106 M-1sec-1 and k
0
ff 1. 31 ± 0. 59 x 10-3 sec-1 • The constant k
0
ff can 
also be more accurately calculated from the relationship 
Using the values of 3. 4 x 10-11 M and 4. 53 x 106 K 1sec-1 for K1 
and k 00 respectively, k 0 ff is found to be 1. 54 x 10
4 sec-1 • 
Inhibitor Studies 
A variety of agents were tested for their effect on the 
hydrolysis of Z-Arg-Arg-AMC (50 µM) by the pepsin-activated 
cathepsin B-like enzyme. Table 6 shows that at a 
concentration of 1 mM, diisopropylfluorophosphate, a known 
serine proteinase inhibitor inhibited the rate of hydrolysis 
by only 12.5%. At the same concentration, 4,4'-
dithiodiphridine and 2,2 1 -dithiodipyridine (thiol proteinase 
inhibitors) exhibited 72 and 100% inhibition, respectively, of 
the the hydrolysis of Z-Arg-Arg-AMC. 
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Table 5. First-order rate constants for approach to steady-
state inhibition of the cathepsin B-like enzyme by leupeptin. 
Active leupeptin cone. k 
3.33 2.30 X 10-3 
5.00 3.21 X 10-3 
7.50 5.16 X 10-3 
10.0 6.71 X 10-3 
20.0 9.95 X 10-3 
8Total leupetin concentration would be 50-fold greater than 
the concentration of the IA form. 
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Fig. 28. Plot of the pseudofirst order rate constant for 
attainment of the inhibited state vs the concentration of 
active inhibitor form of leupeptin. The rate constants k 00 and 
k
0
ff were calculated by fitting the data points to the following 
equation k = k 00 [IA]+ koff by a least squares linear regression 
analysis (Enzfit/Elsevier-Biosoft, Cambridge, UK). [IA] is 
the concentration of the active inhibitor form of leupeptin. 
The slope k
00 
was calculated to be 4. 53 + 0. 55 x 106 M-1sec-1 and 
the intercept koff was found to be 
1.31 ± 0.59 x 10-3 sec-1 • 
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Peptidyl-7-Amino-4-Methylcoumarin (AMC) Substrate Specificity 
Table 7 shows the relative rates of release of AMC from 
several peptidyl-AMC substrates (all at 10 µM) as determined 
by fluorescence measurements. When rates were observed they 
were found to be directly proportional to the substrate 
concentration indicating that the condition ([S]<<Km) 
prevailed. Values of kcatl¾i calculated from v = kcat [E] [SJ, 
¾i 
are shown in Table 7. 
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Table 6. Effect of various agents on cathepsin B-like 
activity. 
Agenta 
diisopropyl fluorophosphate 
4,4'-dithiodipyridine 
2,2 1 -dithiodipyridine 
Concn. 
1 mM 
1 mM 
1 mM 
% Inhibnb 
12 
72 
100 
8The pepsin-activated enzyme was preincubated with the agent 
at the indicated concentration for 45 min at 2s0c. 
bEach value is the mean of triplicate determinations. Activity 
was compared to that of the control enzyme preincubated under 
the same conditions but without the test agent. 
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Table 7. Relative rates of hydrolysis of 
peptidyl-7-amino-4-methylcoumarin substrates. 
Substrate (10 µM) Relative ratea (%) 
Z-Arg-Arg-AMC 100 
Z-Phe-Arg-AMC 1250 
H-Arg-AMC 2.4 
Z-Arg-AMC N0° 
Z-Gly-Gly-Arg-AMC N0° 
Z-Gly-Gly-Leu-AMC N0° 
188 
2351 
4.5 
N0° 
N0° 
N0° 
avalues are relative rates and are compared to Z-Arg-Arg-AMC 
(=100%) 
bThe hydrolysis rates that were observed were directly 
proportional to substrates concentrations. Therefore, under 
this condition ( [ S] <<~) , it was possible to calculate K081/~. 
0Values were too small to detect. 
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CHAPTER V 
DISCUSSION 
Effects of Monensin on Lysosomal Enzyme Targeting 
Fig. 29 summarizes the current understanding of lysosomal 
enzyme targeting in fibroblasts (reviewed in more details 
under "Review of the Related Literature") . Mannose 6-
phosphate receptors (MPRs) bind to newly synthesized lysosomal 
enzymes in the trans Golgi network, thereby segregating them 
from secretory proteins. The lysosomal enzyme-receptor 
complex is then delivered to an intermediate acidified 
compartment where dissociation of the complex occurs. 
Receptors are then returned to the Golgi apparatus and to the 
cell surface for reuse while newly synthesized lysosomal 
enzymes in turn are transferred to the lysosome. A small 
proportion of the lysosomal enzymes (5-20%) are secreted 
before delivery to lysosomes can occur (Kornfeld, 1987). Some 
of these may then be recaptured by receptor-mediated 
endocytosis and redirected to lysosomes via the post-Golgi 
acidified compartment (Kornfeld, 1987). The proteolytic 
processing of lysosomal enzymes is thought to be initiated in 
the intermediate acidified compartment (Mainferme et. al. , 
1985) and is completed in the lysosome (Nishimura and Kato, 
1987) . 
Fig. 29. Biosynthetic transport of lysosomal hydrolases and 
mannose 6-phosphate receptors.-->, transport of unbound acid 
hydrolases; -->, transport of MPR-bound acid hydrolases; and 
==>, recycling of unbound MPR (15, 28). 
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Proton ionophores such as monensin, and weak bases such 
as ammonium chloride, can act to prevent receptor-ligand 
dissociation and receptor recycling (Brown et. al. • 1986; 
Geuze et. al .• 1985) by increasing the pH of acidic 
compartments (Maxfield, 1982). The result can be a deficiency 
of cell surface (Geuze et. al .• 1985) and trans-Golgi-
associated (Brown et. al .• 1986) MPRs, an inhibition of enzyme 
sorting within the trans-Golgi network, and the diversion of 
lysosomal enzymes to a constitutive secretory pathway 
(Nishimura et. al .• 1988). As lysosomal enzymes are diverted 
from degradati ve compartments, proteolytic processing and 
turnover is inhibited (Nishimura et. al.. 1988), and high 
levels of precursor forms should accumulate within the cell 
and in the culture medium. As shown in Figs. 2 and 3, the 
effect of monensin treatment on the secretion of cathepsin B 
and L by 3T3 cells conformed to this description. 
If this explanation of monensin action is correct, and if 
as suggested monensin does not have a large effect on protein 
synthesis per se (Ledger and Tanger, 1984), then the rate of 
accumulation of latent cathepsin Band cathepsin Lin cells 
and media exposed to monensin should provide an estimate of 
V synthesis • The rate of accumulation of latent enzyme in the 
medium in the absence of monensin corresponds to Vsecretion (Fig. 
29) . 
Lysosomal Enzyme Secretion by 3T3 and MMSV Cells 
Using the assumptions described above, the fraction of 
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the newly synthesized cathepsin L which is secreted by 3T3 
cells was calculated to be 0.12 using the data in Fig. 3. 
This is in excellent agreement with the value determined 
independently for NIH/3T3 cells by pulse-chase measurements 
(Dong et. al., 1989). The corresponding values for cathepsin 
B and .B-glucuronidase were 0.17 (Fig.2) and 0.30 {Fig.4), 
respectively. Thus in 3T3 cells, 70% or more of cathepsin B, 
cathepsin Land .B-glucuronidase is routed to lysosomes by a 
monensin sensitive pathway which is presumed to be receptor 
dependent. 
In contrast to 3T3 cells, MMSV-transformed 3T3 cells 
secrete increased amounts of latent cathepsin B, latent 
cathepsin L, and .B-glucuronidase in the absence of monensin 
pretreatment. In addition, monensin is unable to further 
increase the levels of cellular and secreted precursor forms 
of the two cathepsins or to promote the secretion of B-
glucuronidase by MMSV cells. In this way MMSV cells behave 
like 3T3 cells which have been exposed to monesin. Thus, MMSV 
cells appear to be inefficient in targeting enzymes to 
lysosomes, and enzymes which do reach the lysosomes appear to 
travel a pathway which is monensin insensitive. Presumably, 
this pathway is either receptor independent or does not 
require a low pH compartment to function. 
Possible Explanations for the Secretion of Lysosomal Enzymes 
in MMSV Cells 
The observation that MMSV cells appear less efficient 
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than 3T3 cells in targeting enzymes to lysosomes can have 
several explanations. These cells may be unable to form 
phosphorylated mannose oligosaccharides required for high 
affinity binding to MPRs, MMSV cells may be deficient in 
functional MPRs, or MMSV cells may be unable to generate an 
acidic pH gradient along the biosynthetic transport pathway 
for receptor-ligand uncoupling and receptor required 
recycling. Alternatively, MMSV cells may have some other 
fundamental defect in the vesicular transport of enzymes from 
the trans-Golgi network to lysosomes. 
The first explanation can probably be eliminated since 
cathepsin L-secreting Kirsten sarcoma virus transformed NIH 
3T3 cells are capable of producing lysosomal enzymes which 
carry the mannose 6-phosphate targeting signal. 
transformation-related defects in vacuolar 
reduced levels of cell surface and 
In contrast, 
acidification, 
intracellular 
asialoglycoprotein receptors, and deficiencies of lysosomal 
hydrolases have been observed following hepatocarcinogenesis 
(Anderson et al., 1989). Consistent with a vacuolar 
acidification defect, Qiuming Gong in collaboration with the 
author has shown that MMSV cells are deficient in cell surface 
mannose 6-phosphate binding activity compared to 
nontransformed BALB c/3T3 fibroblasts (Achkar et al .• 1990), 
and Valerie Pracht has observed that vacuolar pH in MMSV cells 
is about one half pH unit higher than in the 3T3 cells. This 
pH difference is of sufficient magnitude to inhibit MPR-
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lysosomal enzyme dissociation and MPR recycling to the Golgi 
and cell surface. This would explain the lack of mannose 6-
phosphate binding activity at the cell surface of MMSV-
transformed cells. Thus, it seems possible that the cause of 
lysosomal enzyme secretion in MMSV cells is related to a 
failure in recycling of the MPRs. 
Synthesis of Lysosomal Enzymes in 3T3 and MMSV Cells 
Although the rate of synthesis of cathepsin Lis much 
greater than that of cathepsin Bin 3T3 cells as determined by 
the levels of the latent forms secreted in the presence of 
monensin, cellular levels of both enzymes were similar. This 
cannot be due to the greater rate of secretion of cathepsin L 
than cathepsin B by 3T3 cells, as the fraction of the newly 
synthesized enzyme which was secreted appeared similar for 
both {12 and 17% , respectively). Instead, the unexpected 
similarity in the cellular levels of cathepsin Band cathepsin 
L could be due to the presence of a cathepsin L inhibitor in 
cell extracts which caused an underestimation of active 
cathepsin L activity. Alternatively, the rate of turnover of 
cathepsin L may be greater than that of cathepsin B. 
While increased secretion of procathepsin L by 
transformed fibroblasts is well documented (Gottesman, 1978; 
Gal and Gottesman, 1986; Denhardt et al .• 1986; Troen et al .• 
1987; Dong et al .• 1989), I found that nontransformed 
fibroblasts also secrete 3-fold more latent cathepsin L than 
cathepsin B. Second, I have demonstrated that transformation 
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causes a similar proportionate increase in the secretion of 
cathepsin Bin addition to cathepsin L (17-fold for cathepsin 
Band 27-fold for cathepsin L). The transformation-induced 
increase in cathepsin B secretion is due in part to increased 
expression, as Qiuming Gong has found that the level of 
cathepsin B mRNA is 3-4 fold higher in MMSV cells than in 3T3 
cells (Gong and Frankfater, unpublished results). 
Transformation also produced a 2-fold increase in B-
glucuronidase secretion. 
Previous studies with Kirsten virus transformed NIH 3T3 
cells (KNJH) indicated that transformation caused a selective 
increase in the secretion of cathepsin L. The specificity of 
this secretion was attributed to both an increased expression 
of cathepsin Land to an inability cathepsin L to bind with 
high affinity to mannose 6-phosphate receptors (Dong et al .• 
1989). In agreement, cathepsin L and B-galactosidase are 
reported to be handled differently in KNIH cells, the 
secretion of the former being unaffected by ammonium chloride 
(Sahagian and Gottesman, 1982). In nontransformed fibroblasts 
ammonium chloride and monensin stimulate the secretion of both 
enzymes (Nilsen-Hamilton et al .• 1981). This would suggest 
that mannose 6-phosphate receptor-dependent pathways target 
both cathepsin Land B-galactosidase to lysosomes in 3T3 cells 
but only B-galactosidase in KNIH cells. In contrast, I have 
found that monensin is unable to further stimulate the already 
enhanced secretion of the three lysosomal enzymes which I have 
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examined in MMSV cells, 
secretion by these cells 
indicating that lysosomal enzyme 
is not selective. This could 
indicate a general defect in lysosomal enzyme targeting in 
MMSV cells possibly related to a decreased recycling of MPRs. 
Ammonium chloride stimulation of cathepsin C secretion has 
also been observed in normal hepatocytes but not with Morris 
hepatoma cells (Mainferme et al •• 1985), and hepatocytes but 
not hepatoma cells were found to synthesize measurable levels 
of cation-independent MPR (Mainferme et al. 1985). In 
addition, mutant Chinese hamster ovary cells with altered MPRs 
secrete increased amounts of precursor forms of lysosomal 
hydrolases (Robbins and Myerowitz, 1981). 
Lysosomal Enzyme Secretion by B16 Murine Melanoma Cells 
Previous reports that B16 murine melanoma cells secrete 
a latent cathepsin B-like activity prompted an investigation 
of whether these cells also had a general defect in lysosomal 
enzyme targeting or whether secretion was specific for 
cathepsin B. By comparing the levels of cathepsin B, cathepsin 
L and B-glucuronidase secreted by the two murine melanoma 
variants, B16F-1 and B16a, in the presence and absence of 
monensin, I was able to calculate the fractions of the newly 
synthesized enzymes which were secreted. For latent cathepsin 
L this was calculated to be 0.34 and 0.32 for B16F-1 and B16a 
cells, respectively. The corresponding values for the latent 
cathepsin B-like activity (as defined by the substrate Z-Arg-
Arg-AMC) were 0.38 for B16F-1 cells and 0.44 for B16a cells. 
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In contrast, the fraction of newly synthesized B-glucuronidase 
which was secreted was estimated to be 0.14 and 0.05 for B16F-
1 and B16a cells, respectively. Thus, it appears that B-
glucuronidase is relatively efficiently targeted to lysosomes 
in B16 melanoma cells by a monensin senstive (receptor-
dependent) pathway. In contrast, the latent cathepsin L- and 
cathepsin B-like enzymes appear to be inefficiently targeted 
to lysosomes as 35 to 40% of the estimated newly synthesized 
activities are secreted in the absence of monensin. However 
the targeting defect in B16 melanoma cells is less absolute 
than in MMSV cells where nearly all the cathepsin B and 
cathepsin L appeared to be secreted. 
Effects of Estrogen Treatment on the Synthesis and Secretion 
of Lysosomal Enzymes in MCF-7 Cells 
In breast cancer, estrogens are known to facilitate the 
growth of primary and secondary tumors when these contain 
estrogen receptors {Lippman, 1981). In addition, estrogen is 
known to induce the synthesis and secretion of a Mr 52,000 
protein in estrogen-dependent breast cancer cells (Rochefort 
et al., 1987b). This protein which displays a mitogenic 
effect on dormant MCF7 cells has been identified as a 
precursor of cathepsin D. The corresponding complementary DNA 
has been cloned, and its sequence indicates high homology with 
cathepsin D of normal tissues apart from 5 nucleotide changes 
(Augereau et al., 1988). 
In order to determine whether the effect of estrogen on 
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the MCF7 cells is specific to cathepsin D or whether it 
affects the secretion of other lysosomal enzymes, I examined 
the effect of estrogen stimulation on the secretion of 
cathepsin B, cathepsin Land B-glucuronidase by MCF7 cells. 
Figs. 11, 12 and 13 show no effect of estrogen on the levels 
of these three enzymes in culture media from MCF7 cells and no 
effect on the efficiencies by which these enzymes are targeted 
to lysosomes. The secretion of these enzymes ranged between 
30 and 40%. Thus, it appears that these cells are relatively 
inefficient at targeting enzymes to lysosomes. Selective 
induction of cathepsin D by estrogen results in the appearance 
of a selective increase in cathepsin D secretion. 
Immunodetection of the Cathepsin B-like Activity by MMSV and 
B16a Cells 
Using anticathepsin B polyclonal antibody, I was able to 
detect the mature 28 kDa form of cathepsin Bin cell lysates 
from 3T3, MMSV and B16 melanoma cells, and the precursor 
procathepsin B (40 kDa) secreted by MMSV cells. There were 
almost no changes in the level of secretion of the proenzyme 
upon monensin treatment while the level of the mature enzyme 
in the cell lysates decreased on incubation with monensin 
(Fig. 5). These results are in agreement with those obtained 
by measuring latent and active enzyme activities (Fig. 2). 
These results also indicate that the mature and proenzyme 
forms of cathepsin B can be detected by western blotting after 
SDS PAGE using a polyclonal antibody to cathepsin B. Thus, it 
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appears to be clear that the MMSV cells secrete authentic 
procathepsin B that is responsible for the latent cathepsin B-
like activity using Z-Arg-Arg-AMC as a substrate. 
Western blots using the anticathepsin B antibody were 
able to immunodetect low levels of procathepsin B released 
into the medium by B16a cells. However the levels of this 
proenzyme in the medium increased dramatically when B16a cells 
were treated with monensin. This is very apparant in Fig. 10 
which shows the results of electrophoresis and immunoblotting 
of media samples obtained with and without monensin and 
contain the same amount of Z-Arg-Arg-AMC hydrolase activity. 
It is clear that very much less than expected immunoreactive 
cathepsin Bis present in media in the absence of monensin 
even though a significant amount of latent cathepsin B-like 
activity is detected (Fig. 10). It would therefore appear 
that a second, immuno-unreactive protein is at least partially 
responsible for the Z-Arg-Arg-AMC hydrolase activity detected 
in B16a media in the absence of monensin. In addition, and 
since Fig. 10 shows a dramatic increase in the secretion of 
immunoreactive procathepsin B upon monensin treatment of B16a 
cells, it can be estimated that immunoreactive cathepsin Bis 
efficiently targeted to the lysosomes in B16 melanoma cells as 
was B-glucuronidase. Attempts to detect immunoreactive 
cathepsin Bon a western blot in MCF7 cells and media failed 
due to the low Z-Arg-Arg-AMC hydrolase activity present. 
Relation between Cathepsin B Expression. Secretion of a Latent 
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Cathepsin B-like Activity and Metastasis 
(Qian et al.. 1989) examined the mRNA levels of five 
lysosomal proteinases, cathepsins B, D, H, L, ands, in normal 
mouse tissues and three melanoma variants B16-Fl, B16-F10, and 
B16a, which were selected for differences in their ability to 
colonize the lung following i.v. (tail vein) injection 
(Fidler, 1973). In the i.v. assay, the B16a is more 
metastatic than the B16-Fl (Qian et al .• 1989). Of the five 
cathepsins studied, only the mRNA level of cathepsin B was 
elevated in the highly metastatic melanoma and the mRNA levels 
in the three melanoma variants correlated positively with 
their metastatic potential. The ratio of cathepsin B mRNA 
levels in Bl6F-1, B16 F-10, and B16a was 1:1.5:7 (Qian et al .• 
1989). In agreement with those findings, I observed that the 
intracellular cathepsin B-like activity is 2. 7 times higher in 
cell lysates from B16a than from B16F-1 cells (Table 1). In 
addition, the latent secreted cathepsin B-like activity is 1.6 
times higher in media from B16a cells than from B16F-1 cells. 
In contrast, B16F-1 secrete 1.5 times more latent cathepsin L 
than B16a cells (Table 1). 
Cathepsin B-like activity or cathepsin B mRNA levels have 
been reported to correlate with the metastatic potentials of 
variants of several other tumors, including rat pancreatic 
carcinomas (Koppel et al .• 1984), human genital tract cancers 
(Pietras and Roberts, 1981), and murine hepatoma (Moin et al .• 
1989) . 
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In view of the fact that the levels of the latent 
cathepsin B-like activity secreted by B16 melanoma variants 
was correlated with the message levels for cathepsin B in 
these cells, the finding that the secreted enzyme was · not 
immunoreactive cathepsin B came as a considerable surprise. 
It thus became an important priority to try to identify the 
protein responsible for this latent cathepsin B-like activity. 
The Purification of the Secreted Latent cathepsin B-like 
Enzyme from B16 Cells 
Because western blots of media samples from B16a melanoma 
cells suggested that these cells secrete a latent cathepsin B-
like enzyme that does not cross-react with anticathepsin B-
antibody, it was important to purify the protein responsible 
for this activity. The purification of this enzyme was 
undertaken as described in "Experimental Procedures" and 
"Results". The product appeared better than 95% pure based on 
active site titration with E-64. sos polyacrylamide gel 
electrophoresis under reducing and denaturing conditions gave 
an apparent molecular weight of 67000 for the purified enzyme 
as compared with 70,000 by active site titration. In further 
agreement, the molecular weight of the latent enzyme estimated 
by high performance molecular sieve chromatography was 67,400. 
This cathepsin B-like enzyme was responsible for about half of 
the total avtivity recovered from the anion exchange column. 
When the latent form was preactivated with pepsin, the active 
species eluted at an apparent molecular weight of 55,700. If 
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these results are correct, then the B16 melanoma secreted 
cathepsin B-like activity can not be the translation product 
of the cathepsin B mRNA in mouse (Segunda et al., 1985). 
Those workers have isolated cathepsin B cONA gene clones ·from 
rat liver and found that their translated region encodes a 
polypeptide having a molecular weight of approximately 39,000. 
In order to investigate the possibility that the larger 
molecular weight of the purified enzyme was due either to 
dimerization or to a tight binding inhibitor which also 
blocked the binding of antibodies to the enzyme, a purified 
sample was reduced with mercaptoethanol in 6 M guanidine 
hydrochloride and alkylated with iodoacetate. SOS PAGE in 
Fig. 19 revealed that this treatment actually decreased rather 
than increased the mobility of the purified enzyme arguing 
against this explanation. 
In order to investigate the possibility that 
oligosaccharide chains on the surface of the enzyme might be 
responsible for the higher apparent molecular weight on SOS 
polyacrylamide gels of the purified latent cathepsin B-like 
activity,the reduced and alkylated enzyme was treated with a 
mixture of glycosidase F and endoglycosidase F (see 
"Experimental Procedures") and then analyzed by SOS/PAGE. 
This treatment resulted in a 6kOa decrease in the apparent 
molecular mass of the purified enzyme, but its final molecular 
mass was still greater than that expected for authentic 
procathepsin B. In addition, the apparent molecular mass of 
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the pepsin activated enzyme (55 kDa), determined by high 
perfomance molecular sieve chromatography, is also much higher 
than the reported size of the active cathepsin B in mouse 
mammary gland (31 kDa) (Recklies and Mort, 1985) and rat islet 
cells (31.5 KDa) (Docherty et al .• 1983). 
The sos treated purified latent enzyme failed to cross-
react with antibodies prepared against an SOS-denatured 
cathepsin B-B-galactosidase fusion protein. Pretreating the 
latent enzyme with pepsin prior to SDS denaturation, 
reduction and alkylation of the guanidine hydrochloride 
denatured enzyme also did not increase its immuno-reactivity 
toward anti cathepsin B antibodies (Fig. 10). These results 
provide additional evidence that the purified latent cathepsin 
B-like enzyme is not authentic procathepsin B. As a positive 
control, procathepsin B was detected in culture medium from 
MMSV cells and from B16a cells treated with monensin (Fig. 5) 
by Western immunoblotting. 
Active Site Titration with E-64 
E-64, a known thiol protease inhibitor was able to 
inhibit the Z-Arg-Arg-AMC hydrolase activity of the cathepsin 
B-like enzyme up to 90% in a stoichiometric manner (Fig. 22). 
This indicates that indeed this enzyme is a cysteine protease. 
Extrapolation of the initial linear portion of the inhibition 
curve to 100% inhibition yielded an estimate of the number of 
moles of enzyme which was present in the reaction mixture. 
From a knowledge of the amount of protein also present (as 
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determined by the Bio-Rad method), the molecular weight was 
calculated to be 70,000 as compared with 67,000 and 67,400 
obtained by SDS PAGE and molecular sieve chromatography, 
respectively. 
Kinetic Characterization of the Latent cathepsin B-like Enzyme 
Table 4 shows the values of ~' kcau and kcatl~ for the 
latent cathepsin B-like enzyme after activation with pepsin. 
Values of kcat were calculated from the relationship kcat=Vmaxf (E] 
and kcatl~ was determined from the relationship kcatl~=v/ [E] [S] 
at (S]<<Km. ~ and Vmax were in turn determined by filing 
kinetic data to the Michaelis-Menten equation by non linear 
least squares analysis as described in "Results". For the 
substrate Z-Arg-Arg-AMC, ~ was calculated to be 1.00 ± 0.29 
mM and kcat was O .188 ± . 040 sec-1 • In contrast, the pepsin 
activated procathepsin B secreted by MMSV transformed cells 
had a~ of 0.422 ± .020 mM for the same substrate. These~ 
values are different at a level of statistical significance of 
P<. 025. The value of kcat for the MMSV cell secreted 
procathepsin B could not be determined because the enzyme had 
not been purified. However, kcat and kcatl~ for the activated 
melanoma enzyme is about 840- and 4500- fold less than for 
authentic cathepsin B (Deval et al .• 1990). When Z-Phe-Arg-
AMC was used as the substrate,~ was calculated to be 121 ± 
8 µM, kcat .286 ± .012 s-1 , and kcatl~ 2351 M-1s-1 • In contrast, 
these values for authentic cathepsin B are 252 µM, 364 s-1 and 
1. 44 x 106 M-1s-1 (Deval et al.. 1990). It can be concluded 
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based on this data that the pepsin-activated secreted 
cathepsin B-like enzyme is much less efficient than normal 
cathepsin B in its ability to hydrolyze the synthetic 
substrates Z-Arg-Arg-AMC and Z-Phe-Arg-AMC. 
The pH dependency of the apparent second order rate 
constant kcatll<ui, between pH 3. 5 and pH 8. O, appeared to depend 
on the state of ionization of at least two groups in the free 
enzyme having pKa values of 5.05 and 8.04. The pKa of the 
group controlling the activity of the alkaline limb of the 
titration curve could not be determined with certainty owing 
to the apparent instability of the enzyme above pH 7.5. These 
findings are characteristic of lysosomal cysteine proteinases 
in general, and are similar to the results obtained by Knight 
( 1981) for the hydrolysis of Z-Arg-Arg-2-naphthylamide by 
human liver cathepsin B. Bajkowski and Frankfater (1983) have 
obtained pKa values of 4.2, 5.5 and 8.6 for bovine spleen 
cathepsin B with the substrate Z-Lys p-nitrophenyl ester. 
Overall, these results suggest that the 67kDa latent secreted 
cathepsin B-like enzyme from B16 melanoma cells is a latent 
cysteine proteinase which when activated with pepsin is a 
relatively poor catalyst for the hydrolysis of Z-Arg-Arg-AMC 
and Z-Phe-Arg-AMC. 
Inhibitors of the B16 Melanoma Latent Secreted Cathepsin B-
like Enzyme 
Treatment of the pepsin-activated latent secreted 
cathepsin B-like activity with 1 mM DFP resulted in a 13% 
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inhibition of Z-Arg-Arg-AMC hydrolase activity while 2, 2 ' -
dithiodipyridine, a cysteine protease inhibitor gave 100% 
inhibition. The equilibrium dissociation constant for 
inhibition of the activated cathepsin B-like enzyme by 
leupeptin was calculated to be 1.7x10~ M, a value that falls 
within the range for observed cysteine proteases such as 
papain (Frankfater and Kuppy, 1981) and authentic cathepsin B 
purified from B16 melanoma Cells (Shcultz et al .• 1989). This 
value is however two to three order of magnitude smaller than 
those often seen for leupeptin inhibition of serine proteases. 
Measurements of the rates of association of leupeptin 
with cathepsin B gave a value for the second order rate 
constant, k
00 
of 4. 53 ± 0. 55 x 106 M-1sec·1 as compared with the 
value of 1. 2 x 107 M·1s·1 obtained for the active cathepsin B 
purified from B16 melanoma cells. These values are 
statistically different at a P value of< 0.025. The off rate 
constant was in turn found to be 1. 54 x 104 sec·1 from the 
relationship k 0 ff = K1 x k 00 • This differs from the value of 
1. 78 x 10·3 s·1 for the purified active B16 melanoma cathepsin 
B. 
Although the kinetic data strongly imply that the pepsin-
activated form of the latent cathepsin B-like enzyme from B16 
melanoma is different from active cathepsin B from humans and 
mice, such a conclusion cannot be reached with certainty. 
Thus pepsin may not activate latent cathepsin Bin the same 
manner as procathepsin B which undergoes physiological 
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activation in vivo. Recently Mort et al. has found that the 
peptide bond in procathepsin B cleaved by pepsin in vitro 
differs from the cleavage site for removal of the propeptide 
in vivo. Thus, it might not be unexpected that the 
physiologically activated cathepsin B would have different 
kinetic properties from pepsin-activated purified secreted 
cathepsin B precursor. The only substantial kinetic evidence 
for a difference between the melanoma secreted cathepsin B-
like enzyme and authentic procathepsin Bis the single finding 
that the ~ for the pepsin-activated MMSV secreted enzyme 
differs from the pepsin-activated B16 melanoma secreted 
enzyme. However, taken together with molecular weight 
measurements and determinations of immunoreactivity 
differences, it appears that the cathepsin B-like enzyme 
secreted by B16 melanoma cells is a novel cysteine proteinase. 
The cathepsin B-like enzyme secreted from B16 melanoma 
cells was partially purified earlier by Bajkowski et al .• 
(1984). In agreement with the results of this study, this 
latent cathepsin B-like enzyme appeared as a major band on sos 
PAGE with an apparent molecular weight of 68,000. However, I 
have observed that bovine serum albumin {Mr 68,000) is a major 
contaminant in media samples from B16 melanoma cells 
previously grown in the presence of bovine serum. Furthermore 
I have found that Bl6 melanoma cells also secrete a 65 kDa 
prohormone activating enzyme (unpublished results) and a 63 
kDa serine protease inhibitor homologous to baboon 
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antitrypsin. Given uncertainties in the extent to which 
Bajkowski et al. purified the secreted cathepsin B-like enzyme 
from Bl6 melanoma cells, I can not ascertain whether the 68 
kDa band they observed on sos PAGE was indeed due to·this 
enzyme. 
The cathepsin B-like enzyme secreted by B16 melanoma 
cells may be similar to a 68 kDa secreted Z-Phe-Arg-AMC 
hydrolase activity recently reported to be associated with 
HPC-YP cells and previously mistaken for procathepsin L 
(Yamaguchi et al .• 1989). 
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CHAPTER VI 
CONCLUSIONS 
I. Tumor cells differ in their capacity to secrete 
lysosomal enzymes. MMSV-transformed fibroblasts are 
inefficient at targeting enzymes to lysosomes, secreting high 
levels of cathepsin B, cathepsin Land B-glucuronidase. In 
contrast B16 melanoma cells are efficient in targeting 
immunoreactive cathepsin Band B-glucuronidase to lysosomes. 
However these cells secrete about 45% of their newly 
aynthsized pro-cathepsin L. 
II. The cathepsin B-like activity secreted by B16 
melanoma cells is due to a new enzyme species having a 
molecular weight of 67,000. The pepsin-activated form of this 
enzyme is a less efficient catalyst of Z-Arg-Arg-AMC and z-
Phe-Arg-AMC hydrolysis than is the mature form of cathepsin B 
from rodent tissues. 
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